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Foreword
It gives me particular pleasure to present with this publication the results of
the risk assessment undertaken by the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) on the substance gamma-hydroxybutyric
acid (GHB). The risk assessment was carried out under the terms of a joint
action adopted on 16 June 1997 by the Council of the European Union (1)
and is the fourth such exercise undertaken to date by the EMCDDA (2).
GHB has been used experimentally in human medicine for 30 years, but
since the mid-1990s has been surfacing as a recreational drug. Some
EU countries have reported concern over GHB’s surreptitious use in sexual
assaults.
Information on the patterns of use and implications for illegal drugs-trafficking
networks were collected through the EMCDDA’s early warning system via the
European network of national focal points and Europol’s national units. On
the basis of the findings, the Horizontal working party on drugs of the
European Council requested a risk-assessment procedure to be carried out
which reviewed the pharmacotoxicological data on GHB and assessed the
public health risks and the available sociological and criminological evi-
dence. The resulting ‘Report on the risk assessment of GHB’ was presented to
the Council in March 2001. On the basis of the report, the Council request-
ed the EMCDDA and Europol to ‘actively’ monitor GHB until the end of 2001
— its consumption, trafficking and the public health-related problems linked
to it as well as its clinical effects, prevalence and patterns of use, seizures, the
role of organised crime in production, diversion and trafficking and the role
of the Internet in marketing the drug for non-medical use.
(1) Joint action concerning the ‘information exchange, risk assessment and the control of new
synthetic drugs’ (OJ L 167, 25.6.1997). A joint action is a decision adopted unanimously by
the EU Member States within the framework of the third pillar of the Treaty on European
Union (cooperation in the field of justice and home affairs). Synthetic drugs are psychoac-
tive substances produced in laboratories and not derived from natural products. They
include MDMA (ecstasy), other amphetamines and LSD.
(2) The three previous risk-assessment exercises concerned the substances N-methyl-1-(1,3-ben-
zodioxol-5-yl)-2-butanamine (MBDB), 4-methylthioamphetamine (4-MTA) and ketamine.
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I would like to thank all of those who participated in the risk-assessment
process for the high-quality work carried out. I trust that the results present-
ed here will make a significant contribution to the knowledge pool on GHB
and that they prove to be a valuable resource to politicians responsible for
the final decision on control and prevention measures.
Georges Estievenart
Executive Director, EMCDDA
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Abbreviations
ACh acetylcholine
BP blood pressure
bpm beats per minute
CAS chemical abstracts registration
DA dopamine
EEG electroencephalogram
GABA gamma-aminobutyric acid
GBL gamma-butyrolactone
GC-FID gas chromatography with flame ionisation
GC-MS gas chromatography with mass spectrometry
GHB gamma-hydroxybutyric acid or gamma-hydroxybutyrate
GCS Glasgow coma score
KGHB GHB potassium salt
i.p. intraperitoneal
i.m. intramuscular
i.v. intravenous
MAO monoamine oxidase
MDMA 3,4-Methylenedioxy-N-methylamphetamine
NA noradrenaline (norepinephrine)
NaGHB GHB sodium salt
SSRI selective serotonin reuptake inhibitor
5-HT 5-hydroxytryptamine (serotonin)
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Introduction
A risk assessment of any chemical is a unique scientific event in which a
range of evidence is evaluated and discussed in depth. Risk assessments of
new synthetic drugs under the aegis of the joint action of July 1997 are even
more unique because not only the pharmacotoxicological effects on health
must be considered but also the social effects and the possible consequences
of prohibition. The risk assessments performed in September 2000 on keta-
mine (3) and GHB were respectively the third and fourth such risk assess-
ments performed by the extended Scientific Committee at the EMCDDA. The
unique feature of both these substances is that they are both licensed medi-
cines of value in human or veterinary medicine. The task faced by the risk-
assessment committee therefore involved not just an assessment of the sci-
entific evidence but also an assessment of how best to safeguard public
health while simultaneously ensuring that valuable medicines could still be
available to practitioners and their human (and animal) patients. These
assessments involved detailed and robust discussions among the multidisci-
plinary committee, drawn from each of the Member States. The ability of sci-
entists from a range of laboratory and non-laboratory sciences to debate the
issues surrounding new synthetic drugs is a key strength of the joint action
process and my colleagues on the Committee are to be commended on their
detailed and learned contributions to our overall understanding of these two
substances. Their individual contributions allied to those of the two experts,
Dr Leon van Aerts (ketamine) and Mr Simon Elliott (GHB) plus the invaluable
inputs from the staff of the Monitoring Centre provided the basis for the final
recommendations made to Council about the two drugs. These recommen-
dations relate not only to the question of control of ketamine and GHB but
also highlight the need for the Member States to consider other elements
such as the need for research on the neurotoxicity of ketamine and on the
role of GHB (and other drugs) in cases of drug-assisted sexual assault. Given
that these subsidiary recommendations come from a Committee composed
of the leading experts on new synthetic drugs in the EU, their importance
should not be underestimated by the Commission, the Council or the
Member States.
(3) The ‘Report on the risk assessment of ketamine in the framework of the joint action on new
synthetic drugs’ is also available.
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As ever in these risk assessments an enormous debt of gratitude is due to my
colleagues on the steering committee for risk assessment who worked
incredibly hard before, during and after the meetings to finalise the reports.
The work of Salme Ahlström (Finland), Aldo Perissino (Belgium), Wolfgang
Werdenich (Austria), Jean-Pol Tassin (France) and Christina Poethko-Müller
(Germany) was more than matched by the efforts of the staff of the Centre
including Alain Wallon, Lena Westberg and Deborah Olszewski.
My admiration of all of them has grown with each risk assessment because of
their acumen, commitment and enthusiasm for a unique European activity.
Dr Desmond Corrigan
Chairperson, Scientific Committee of the EMCDDA
10
Report on the risk assessment of GHB 
in the framework of the joint action 
on new synthetic drugs
On 17 April 2000, the Portuguese Presidency of the European Council for-
mally notified gamma-hydroxybutyric acid (GHB) for risk assessment under
Article 4 of the joint action on new synthetic drugs of 16 June 1997.
A meeting of the Scientific Committee of the EMCDDA, extended with
experts nominated by the Member States and representatives of the
European Commission, Europol and the European Agency for the Evaluation
of Medicinal Products (EMEA), to assess the health and social risks — as well
as the possible consequences of prohibition — of GHB was held on 25 and
26 September 2000.
The meeting considered the following documents:
 ‘Review of the pharmacotoxicological data on gamma-hydroxybutyric
acid (GHB)’, report to the EMCDDA;
 ‘Public health risks of GHB: epidemiological evidence’, EMCDDA;
 ‘Sociological and criminological evidence on the risks of GHB’, EMCDDA;
 Europol’s contribution to the risk assessment of GHB; and
 EMEA’s contribution to the risk assessment of GHB.
These documents, in conjunction with further information and comments
from the expert participants, formed the basis of the risk assessment reported
below.
1. Chemical description
Gamma-hydroxybutyric acid refers to the protonated form whereas gamma-
hydroxybutyrate refers to the deprotonated form of the carboxylic acid
moiety. The abbreviation GHB refers to both of these chemical names. Other
chemical names include oxybate, 4-hydroxybutanoic acid, and 4-hydroxy-
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butyric acid. GHB can also form various salts (for example, sodium and
potassium salts) which are soluble in water and methanol.
GHB was initially developed as an anaesthetic agent but was later found to
be a naturally occurring compound in mammalian brain and tissue, existing
as a by-product of GABA metabolism and putative neurotransmitter. Major
chemical and metabolic precursors include gamma-butyrolactone (GBL) and
1,4-butanediol which are both rapidly converted to GHB in the body.
Registered names for GHB are: Alcover, Somsanit, Gamma-OH.
GHB has various street names including ‘liquid ecstasy’, ‘liquid E’, ‘GBH’,
‘easy lay’, ‘scoop’, ‘liquid X’, ‘fantasy’ and ‘cherry meth’.
2. Pharmaceutical description
Pharmaceutically, GHB is available as sodium gamma-hydroxybutyrate in
liquid form. Recreationally, GHB is available as either a liquid formulation
or as a powder (either loose or in tablets or sometimes in a capsule).
GHB is used therapeutically in anaesthesia, in the treatment of alcohol with-
drawal and in long-term sedation, and is being investigated for the treatment
of narcolepsy-associated cataplexy. It is a licensed medicine for human use in
only four Member States. GHB is not authorised for veterinary use. There are
no known reported industrial uses of GHB, however, GBL and 1,4-butanediol
have many uses in various industrial processes.
3. Health risks
3.1. Individual health risks
(a) Acute effects: Evidence relating to the activity of GHB on neurotransmitter
systems is largely contradictory. However, it is believed that GHB binds to
GABA B and GHB-specific receptors. It blocks dopamine release at the
synapse and produces an increase in intracellular (neuronal) dopamine. This
is followed by a time-dependent or dose-dependent non-functional leakage
of dopamine from the neurone. In addition, GHB does not appear to be a
monoamine oxidase (MAO) inhibitor.
GHB has been reported to lengthen slow-wave/delta sleep without a
decrease in oxygen consumption while the respiratory centre remains sensi-
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tive to carbon dioxide. It also induces anaesthesia but does not provide pain
relief. An increase in growth hormone and prolactin release has been reported
in one study of six human subjects.
GHB can cross the blood-brain barrier and is rapidly absorbed and
metabolised, possessing a plasma half-life of approximately 20 minutes. It
also has a steep dose-response curve, where a small increase in the dose can
cause sedation as opposed to just nausea. Following an oral dose, effects
usually occur after 15 minutes and can last up to 7 hours, depending on the
dose.
At present there are no animal or human data concerning reproductive tox-
icity, neurotoxicity or the mutagenicity and carcinogenic potential of GHB.
However, animal and human studies indicate that GHB toxicity is dose-
dependent and can result in nausea, vomiting, hypotonia, bradycardia,
hypothermia, random clonic movements, coma, respiratory depression and
apnoea.
Other depressant or sedative drugs (e.g. opiates, benzodiazepines, alcohol
and barbiturates) and possibly other psychoactive compounds (e.g. amphet-
amine) can exacerbate the toxic effects of GHB ingestion.
Reported subjective effects of GHB use include: euphoria, hallucinations,
relaxation and disinhibition.
(b) Clinical effects: GHB has been associated with 11 deaths in the EU
between September 1995 and January 2000: four in the United Kingdom,
four in Sweden, two in Finland and one in Denmark. Two deaths have been
reported in Norway. Deaths involving solely GHB appear to be rare. The
majority of these cases have involved the ‘recreational’ abuse of GHB for its
subjective euphoric (‘high’) effects, primarily by young adults. The mode of
GHB abuse frequently involves the use of other drugs such as alcohol or
MDMA.
Non-fatal hospital admissions associated with GHB are difficult to assess as
GHB analysis is not routinely performed by hospital toxicology laboratories.
However, there have been at least 200 reported GHB overdose cases in
Europe (in particular in Sweden, the United Kingdom, the Netherlands,
Denmark, Belgium, Finland, Spain and Norway). Clinical management of
such patients can be quite difficult, posing risks to both patients and staff.
(c) Dependence: There have been few studies regarding the dependence
potential of GHB. However, during studies involving administration of GHB
to patients at varying concentrations, no dependence has been observed at
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low doses of GHB. At prolonged high doses, however, physical dependence
as evidenced by a withdrawal syndrome has been noted in some cases and
included symptoms of insomnia, muscular cramping, tremor and anxiety.
(d) Psychological effects: There is limited published data concerning specific
psychological effects of GHB either acutely or chronically, therefore the
exact effect of GHB on cognition, mood and psychomotor ability is unclear.
However, the effects of GHB on the central nervous system have implica-
tions for the ability to drive and to operate machinery.
3.2. Public health risks
(a) Availability and quality: Preparations containing GHB have marketing
authorisation (4) in four countries: in Austria and Italy for alcoholic craving
and in France and Germany as an anaesthetic. Growing concern about non-
medical use of GHB in Europe as well as in the United States and in Australia
has prompted a number of these countries to introduce new and more strin-
gent controls on GHB. The disruption of overt supply has lead to distribution
patterns similar to illicit drug networks.
More discreet methods have therefore been adopted by suppliers of GHB
alongside the appearance of substitutes for GHB in name or content as well
as the development of a home-made ‘kitchen-sink’ GHB industry due to the
fact that it is easily manufactured and no special equipment is required for
this process. However, there have been some reports of burns to mouths due
to high caustic soda content in home-made preparations.
In dance settings, GHB is frequently sold in liquid form in small 3 ml plastic
bottles containing approximately 3 g of GHB, where it is used socially for
relaxation, mild euphoria or post-party for sleep. Pharmaceutical-grade GHB
is also available through the Internet, catalogue sales and specialist shops in
some countries. This market has recently been curtailed by legislation and
bad publicity.
On the basis of the available information, it is generally suggested that a
0.5 g dose be taken for relaxation and disinhibition, a 1g dose for euphoric
effect, and a 2–3 g dose for deep sleep.
(4) Classification for the supply of medicinal products for human use is regulated by Directive
92/26/EEC of 31 March 1992, and Article 12 of Directive 75/319/EEC of 20 May 1975 reg-
ulates through the Committee for Proprietary Medicinal Products (CPMP) the suspensions,
withdrawal or variations to the terms of the marketing authorisation, in particular to take
account of the information collected in accordance with Pharmacovigilance.
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(b) Knowledge and perception of GHB among users: Although media report-
ing of GHB is limited, information is available to the populations who use
recreational drugs, smart drugs or body-building drugs, via associated social
networks. A vast number of Internet sites and newsgroups promote the use
of GHB for a wide rage of purposes which include: inducing sleep, mood
enhancement, treatment of drug and alcohol withdrawal, sexual enhance-
ment, body-building and anti-ageing.
(c) Prevalence and patterns of use: There are no data specifically on preva-
lence or patterns of the use of GHB and at present there is little evidence that
GHB is used on a wide scale in any Member State.
Anecdotal and Internet reports suggest that use of GHB may not be confined
to recreational party drug settings. Some sub-populations appear to use GHB
for desired specific effects. Internet postings and outreach workers suggest
that GHB can also be used as a substitute for alcohol or drugs to achieve ine-
briation whilst avoiding detection tests in treatment, the workplace, and for
driving. Some police sources and media cover have expressed concern
about the ease with which GHB may be used to facilitate sexual assault, but
the extent of this is unclear. In this regard, it should be noted that GHB dis-
solves easily and is colourless, odourless and may be difficult to taste. It can
therefore be taken unobtrusively in social settings where drinks are served.
(d) Characteristics and behaviour of users: There is limited information avail-
able concerning the characteristics and behaviour of users. Within recre-
ational drug settings, anecdotal reports from youth media and drug workers
suggest that the negative effects of GHB may lead to a negative image for the
drug. However, it should be noted that the comparatively low price of GHB
provides a cheap alternative to alcohol and when used for illicit purposes the
effects of GHB are much closer to those produced by alcohol, cannabis and
benzodiazepines, than they are to MDMA and other stimulant drugs. The
physical incapacity and unconsciousness resulting from a relatively small
increase in GHB doses demonstrates that health risks in relation to road traf-
fic or operating machinery are high.
(e) Indicators of health consequences: There is no information on the health
consequences for the general population. GHB has been associated with 11
deaths in the EU between September 1995 and January 2000: four in the
United Kingdom, four in Sweden, two in Finland, and one in Denmark. In
addition, two deaths have been reported in Norway.
Non-fatal hospital admissions associated with GHB are difficult to assess as
GHB analysis is not routinely performed by hospital toxicology laboratories.
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However, there have been at least 200 reported GHB overdose cases in
Europe (in particular in Sweden, the United Kingdom, the Netherlands,
Denmark, Belgium, Finland, Spain and Norway).
(f) Context of use: An important factor with regard to context of use is the
lack of reliable indications of dose accompanying sales of GHB at ‘street
level’. However, the steep dose response curve of GHB makes it risky for
recreational use even where dose is both accurately measured and known.
The combination of GHB with other drugs, particularly alcohol and other
sedative drugs, also substantially increases the risks related to taking GHB.
4. Social risks: sociological/criminological aspects
4.1. Sociological aspects
(a) Social consequences: The social consequences for the user are mainly
related to the steep dose-response curve and unpredictable dose resulting in
loss of physical control and consciousness, and to the ingestion of caustic
soda.
(b) Consequences for the social behaviour of the user: There is anecdotal evi-
dence of clumsy behaviour, vomiting and loss of consciousness in dance set-
tings which is regarded unfavourably by music promoters, club owners and
youth media journalists.
(c) Other social consequences: The ease with which GHB can be acquired
or manufactured allows more consumer power than that usually found in
illicit drug markets in the EU. The use of GHB to induce relaxation and sleep
promotes the concept of illicit drug use for self-medication purposes rather
than hedonism.
The similarity to alcohol regarding effects and route of administration may
facilitate diffusion, i.e. in the absence of major value conflicts about use. In
view of the pharmacological effects and known health risks, there are impli-
cations for a number of social institutions: the media, drug outreach work-
ers, research institutes, hospital emergency departments, community drug
and rape services, and the police.
A range of factors such as low price, ease of availability and administration,
lack of information, the need for sedation following heavy stimulant use, and
careless media coverage, increase the probability of GHB diffusion and con-
sequent harm. Other factors, such as antisocial effects, relatively short dura-
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tion, and its low-status image, mitigate against widespread diffusion and so
decrease the probability of harm.
4.2. Criminological aspects
No Member State has information on large-scale production, trafficking and
distribution of GHB. Seizures of GHB in the EU are very small when com-
pared to seizures of ‘regular’ types of synthetic drugs such as amphetamine,
MDMA and MDA.
Three Member States — France, the Netherlands and the United Kingdom —
have information on illicit production of GHB in their country. Production in
France seems to be incidental and limited to one ‘kitchen’-type facility.
Two Member States — the Netherlands and the United Kingdom — report
on the role of organised crime in the production, trafficking and distribution
of GHB. In both countries producers of GHB are thought to also be involved
in the production of controlled drugs, with dealers possibly having links to
ecstasy producers. They are individuals with a criminal background or mem-
bers of small groups, rather than criminal networks.
A particular consequence that has been linked with GHB by some media
and police reports is the potential for GHB to be used surreptitiously for sex-
ual purposes, possibly including rape.
5. Possible consequences of prohibition
5.1. Legal status
An analysis of the legal status of GHB in the 15 Member States shows that
the drug is controlled under the misuse of drugs legislation in six of them:
Belgium, Denmark, France, Ireland, Italy and Sweden. It is similarly con-
trolled in Norway. GHB is controlled by the Medicines Act in Austria,
Finland, Germany and the Netherlands. In the United Kingdom where its
manufacture and supply fall within the scope of the Medicines Act, consid-
eration is being given to controlling GHB under the misuse of drugs legisla-
tion. In Greece and in the Netherlands, it is subject to monitoring.
The precursor GBL (gamma-butyrolactone) is currently on the voluntary
monitoring list of the Drug Precursors Committee of the European
Commission. The other precursor of GHB — 1,4-butanediol — is not on this
list. The list is circulated to the chemical industry, members of which are
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asked to notify any suspicious enquiries and transactions in the chemicals to
the competent authorities. There are no formal controls on the chemical.
5.2. Possible consequences of prohibition
The possible consequences of prohibition were discussed at the meeting and
included the points listed below.
 The EMEA drew attention to the existence on the market of authorised
medicines containing GHB in four Member States and the possibility of an
application for Orphan Drug Designation for GHB being submitted in light
of the submission to the US-FDA (US-Food and Federal Administration).
The EMEA also highlighted the fact that changes in the conditions of mar-
keting authorisations for GHB containing medicinal products proposed by
the meeting should be dealt with at national level.
 The meeting was informed of the results of a critical review of GHB by the
32nd WHO Expert Committee on Drug Dependence which recommend-
ed to the Commission on Narcotic Drugs (CND) that GHB be listed in
Schedule IV of the 1971 United Nations Convention on Psychotropic
Substances. It was pointed out that it was for the CND to decide whether
or not to accept this recommendation.
 It was reported by a number of participants that Member States who had
subjected GHB to control had noted a reduction in intoxications involving
GHB. It was pointed out that following a decision not to control GHB in
one Member State, a reduction in non-fatal emergencies was also
observed. Systematic data, however, was unavailable in both instances.
 Concern was expressed about the possible impact of prohibition on the
licit production of GBL and 1,4-butanediol because of the high level of
production and the wide range of industrial applications for both com-
pounds.
 Concern was also expressed about the negative effects of prohibition on
black market conditions.
 Considerable debate took place about the possible methods of control.
One opinion was that medicines legislation (5) was sufficient because it
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(5) That is to say EU Regulation based upon Council Directive 65/65/EEC of 26 January 1965,
as amended by Directives 83/570/EEC, 87/21/EEC, 89/341/EEC and 93/39/EEC, as well as
Decisions of the Court of Justice of the European Communities, especially Case C-112/89.
could permit seizure of products and prevent both advertising and sale of
such products. Other participants were of the view that medicines legisla-
tion was insufficient and that stronger measures of control were necessary.
It was pointed out that such strong measures of control did not mean that
the consumer should be punished. Doubt was expressed as to whether
medicines legislation would be effective where no marketing authorisa-
tions were in place and it was recommended that this point should be fur-
ther investigated.
6. Conclusions
The Scientific Committee of the EMCDDA, extended with experts from the
Member States, and representatives of the Commission, Europol and the
EMEA, have considered the health and social risks as well as the possible
consequences of prohibition of GHB and in accordance with Article 4 of the
joint action, submit the following conclusions:
6.1. GHB is not a new synthetic drug. It has therapeutic potential and prepa-
rations containing it are registered medicines in four Member States. It
is also used in recreational settings.
6.2. GHB has anaesthetic and sedative properties. In recreational use, the dose
margin between the desired and the serious adverse effects is narrow.
Because of the effects of the drug, the levels of fatal and non-fatal emer-
gencies and reports of dependency, GHB is considered to pose signifi-
cant risks to health. The possible involvement of GHB in drug-assisted
sexual assaults was of concern even though the extent of this involve-
ment is unclear.
6.3. An opinion which received significant support at the meeting was that
this substance should be subjected to more stringent control measures
than the medicines legislation.
6.4. Another opinion was that control through medicines legislation is suffi-
cient.
6.5. The meeting noted that the precursor GBL was rapidly converted to GHB
both within and outside the body whereas the precursor 1,4-butanediol
was rapidly converted within the body. Noting that GBL is included in
the monitoring programme under the Precursor Regulations, the meet-
ing recommended that the Drug Precursors Committee set up under
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Article 10 of Regulation 3677/90/EEC and Directive 92/109/EEC should
strongly consider the inclusion of 1,4-butanediol within the monitoring
system.
6.6. The Committee recommended that Member States should consider con-
vening an expert group to consider the role of GHB and other drugs in
cases of sexual assault.
6.7. The meeting noted that biological samples could contain levels of GHB
in circumstances where there was no evidence of GHB consumption
and recommended that this phenomenon should be the subject of fur-
ther study with a view to establishing guidance for best practice in the
handling and analysis of biological samples containing GHB.
6.8. The meeting highlighted the need to target objective information on
GHB to existing and potential users as well as to key professional
groups.
Lisbon, 26 September 2000
Europol–EMCDDA progress report on GHB
in accordance with Article 3 of the joint
action of 16 June 1997 concerning the
information exchange, risk assessment and 
the control of new synthetic drugs
Introduction
The Horizontal Working Party on Drugs, at its meeting of 22 September
1999, requested the EMCDDA and Europol to provide preliminary informa-
tion on the substance GHB under Article 3 of the joint action. Europol
national units and Reitox national focal points were subsequently requested
to provide information on GHB. The EMCDDA and Europol also conducted
enquiries. No reporting took place using the ‘Europol–EMCDDA reporting
form on new synthetic drugs’.
Six Member States have decided to put GHB under permanent control:
Belgium (Royal Decree 22.1.1998); Denmark (Euphorians Act, 16.12.1999);
France (Decree 28.4.1999); Ireland (Misuse of Drugs Act, May 1999); Italy
(Decree 266, 11.11.1999); and Sweden (Narcotics Act, 13.1.2000).
In Austria, Finland and Germany, GHB is controlled by the Medicines Act.
In Greece, it is subject to monitoring. In the United Kingdom, the Advisory
Council of the Misuse of Drugs recommended monitoring of GHB misuse;
its manufacture and supply fall within the scope of the Medicines Act 1968.
In the Netherlands, GHB has been controlled by the Medicines Act since
1996. In October 1999, the Dutch Coordination Centre for Assessment and
Monitoring of New Drugs of Misuse (CAM) concluded its risk assessment on
GHB and recommended continued monitoring and a further risk assessment
in case of new evidence.
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Available information on GHB
Chemical and physical description, including the name under which GHB
is known
The full chemical name for GHB is gamma-hydroxybutyrate.
Figure 1: Structural formula of GHB
GHB is known by a variety of street names: ‘liquid ecstasy’, ‘gamma-OH’,
‘oxybate’, ‘somatomax’, ‘GBH’, ‘happiness drops’, ‘liquid loving’ and others.
It is usually available as a clear, odourless, colourless and sometimes taste-
less liquid. The substance is most frequently sold in plastic bottles or in cap-
sules. It is also available in the form of white powder tablets.
GHB was originally developed as an anaesthetic drug and is used as a
licensed medicine in some Member States. It acts as a central nervous system
depressant and hypnotic and is chemically related to the brain neurotrans-
mitter gamma-aminobutyric acid (GABA). In some Member States, GHB is
offered for retail sale through shops, the Internet and magazine advertise-
ments. The typical dose is around 10 ml equivalent to about 1g of GHB.
GHB is absorbed within 10–15 minutes and in adverse circumstances nei-
ther flumazenil nor naloxone appear to be effective. GHB cannot be detect-
ed in blood or urine by means of routine toxicological analysis, nor does it
react with the reagents in commonly used field-test kits. Suitable methods of
identifying GHB in the laboratory are NMR and infrared spectroscopy.
Information on the frequency, circumstances and/or quantities in which
GHB is encountered
In Austria, although there have been no reported seizures or hospital treat-
ment episodes attributed to GHB, there is some anecdotal evidence of use
among very small, closed groups.
In Belgium there are regular seizures, particularly during the summertime, of
small quantities of GHB in liquid form and, incidentally, in capsules. In
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September 1999, there was a report of two cases of hospitalisation near the
French border. GHB was suspected but results from blood sample analysis
have not been made available yet.
In Finland, 757 millilitres of GHB were seized in seven incidents in 1998. In
1999, the Finnish forensic laboratories analysed samples of GHB relating to
total seizures of over 3 800 grams. Also, over 5 litres of the precursor GBL
were seized.
In France, there have been few seizures reported and no reported fatal or
non-fatal intoxications. A survey, which compared 900 young people who
regularly attended techno party events with a control group matched for age
and sex of people who do not attend such events, found that 4 % of techno
party attenders said they had taken GHB. Among the control group, con-
sumption of GHB was non-existent indicating that the use is not widespread.
According to the French Centre d’Evaluation et d’Informations sur les
Pharmacodependances, abuse of 1,4-butanediol as a substitute for GHB has
increased since the classification of the latter under French legislation, in
April 1999. The substance 1,4-butanediol is being sold as ‘ecstasy’.
In Denmark, there have been five seizures of GHB since June 1999 and in
the same period 12 patients with non-fatal intoxications associated with
GHB have been treated in hospital.
Germany reports some incidents of seizures of small, insignificant quantities
of GHB.
In Ireland, one seizure of GHB in liquid (25 millilitres) and one in powder
form were reported.
In the Netherlands, there were a number of small seizures from discothe-
ques. At least eight hospitalised, non-fatal intoxications associated with GHB
have been recorded. Producers of GHB are thought to be involved in the
production of controlled drugs, with dealers possibly having links to ecstasy
producers. They are individuals with a criminal background or members of
small groups, rather than criminal networks.
In Spain, the first seizure took place in Madrid in January 1996. From 1996
to November 1999, a total of 16 small seizures were reported. Since 1995,
one non-fatal intoxication was registered. On the basis of current evidence,
GHB use in Spain is thought to be very limited (Cabrera et al., 1998).
In Sweden, seizures have found GHB in connection with other seizures of
narcotic drugs and anabolic steroids. In 1997, one seizure of 50 kg was
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reported, and in 1998 one seizure of 13.5 and 20 litres as well as some small
seizures.
In the United Kingdom, London, the North-West, the Midlands and South
Wales have been identified as the main areas of production and supply. GHB
is mainly distributed through retail outlets and over the Internet. Proactive
enforcement against sale and supply of GHB via retail outlets has curtailed
the overt advertising and supply of GHB, particularly in London’s sex shops.
The disruption of overt supply has led to distribution patterns similar to those
of illicit drug networks. In addition, the Medicines Control Agency (MCA)
has taken action against a number of unlicensed operators. There is little evi-
dence of widespread use or that illicit use is increasing. GHB is supplied to
bodybuilders via mail order and in gyms. Seizures are rarely submitted for
laboratory examination. The Forensic Science Service handles less than 10
cases each year. There is no current intelligence regarding international traf-
ficking of GHB into or from the United Kingdom. There is intelligence that
the precursor, GBL, is being sourced from other Member States, for example
Belgium, to be used in GHB production. The high profit margins and the
comparatively limited penalties encourage the involvement of organised
criminal groups. There is evidence of criminals involved in controlled drugs
also being involved in the production and supply of GHB.
A first indication of the possible risks associated with GHB
In small doses (10 mg/kg body weight) GHB diminishes tension but in margin-
ally larger doses (50–70 mg/kg body weight) it can cause nausea, vomiting,
confusion, convulsion, anaesthesia, apoplexy, respiratory depression and
coma.
It has been stated that adverse effects occurred both when GHB was used
alone or in combination with other drugs and alcohol (Williams et al., 1998).
The risks of GHB consumption are more severe when taken with alcohol and
drugs such as benzodiazepines, barbiturates, opiates, anti-convulsants, and
antihistamines.
GHB use could lead to the development of physical dependence (Galloway
et al., 1997).
The earliest recorded indications of illicit use of GHB were in Sweden and
in the United States during the early 1990s. At that time in Sweden, the small
number of GHB overdoses was associated with bodybuilders.
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Since 1995, eight deaths linked to GHB use have been reported within the
European Union (6). In September 1995, March 1996, November 1997 and
January 1999, four deaths were reported from the United Kingdom. In
February 1996 and in March 1997, two deaths were reported from Sweden.
Alcohol was implicated in each of the deaths in Sweden and the United
Kingdom. In 1998 and in 1999, two deaths were reported from Finland.
A substantial number of hospital admissions and comas associated with a
combination of GHB and alcohol were reported from the United Kingdom,
Sweden and the Netherlands. In the Netherlands, the conclusion of the risk
assessment on GHB for continued monitoring was based mainly on the dan-
ger the drug presented for individual health, due to the fact that the desired
effect and the dosage to cause unconsciousness or reversible coma are
closely linked to each other.
Information on chemical precursors
The precursor to GHB is gamma-butyrolactone (GBL), a solvent widely used
in industry and commercially available. GHB is easily manufactured by
adding aqueous sodium hydroxide to gamma-butyrolactone (GBL). No special
equipment is required for this process. A major technical difficulty facing
control of GHB is that the chemical reaction above is reversible. The pre-
cursor can simply be recovered from a GHB solution by adding acid to neu-
tralise the sodium hydroxide. Because of the wide use of these chemicals,
the monitoring of sales in Europe does not offer a feasible method of identi-
fying illicit production.
Information on the mode and scope of established or expected use of
GHB as a psychotropic substance
Effects of GHB are more similar to those produced by alcohol, marijuana
and diazepam, than they are to MDMA and other stimulant drugs. Although
GHB may be distributed through the same market as ecstasy, it is not likely
to be purchased as or mistaken for ecstasy because of its distinguishing physical
appearance and effects. GHB dissolves easily and is colourless, odourless
and sometimes tasteless. Therefore, it can be taken easily and unobtrusively
in social settings where alcoholic drinks are served. The comparatively low
price of GHB may provide a cheap alternative to alcohol for young people
on low incomes.
(6) In 1993, one death, which occurred in association with heroin use, was recorded in Italy.
The reasons given by the techno party attenders in the French survey for
taking GHB included the effects induced by taking it. Additional reasons
were that in association with other substances it enhanced the overall effects
or facilitated the ‘come down’ from taking stimulant drugs.
There is little evidence that GHB is abused on a wide scale in any Member
State. In parts of the United Kingdom, GHB use is reported as being estab-
lished on the ‘gay scene’ and it is thought to have made some inroads into
the ‘heterosexual scene’. Anecdotal and media reports have suggested that
GHB has widespread potential for being surreptitiously added to drinks for
sexual purposes, including rape.
Books about GHB are available and information about recipes, taste, effects
and where to purchase supplies is commonly exchanged via the Internet.
Information on other use of GHB and the extent of such use
There are claims that GHB has anabolic properties and bodybuilders there-
fore use it. Internet discussion groups and other media provide evidence that
GHB is used outside of the ‘dance scene’ for a number of reasons such as:
to induce sleep, as a substitute for alcohol, and for sexual purposes and
relaxation.
Drafted by Europol and EMCDDA
17 March 2000
Use of GHB as a medicinal product (EMEA)
As part of the preparation for the risk assessment of GHB, the European
Agency for the Evaluation of Medicinal Products (EMEA) asked for informa-
tion on the national situation of this product in terms of authorisation and
therapeutic value.
According to the responses received, GHB is authorised only in four coun-
tries: in Italy and Austria for alcohol craving, and in France and in Germany
as an anaesthetic. In Germany it was put on the market before the German
Medicines Act came into force in 1978. Sales figures were not provided but
it can be assumed that they are low. GHB is subject to restricted prescription
in France and is regulated as a psychotropic substance in Italy.
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Review of the pharmacotoxicological data on
gamma-hydroxybutyric acid (GHB) (7)
This report was commissioned by the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) as a background paper for the risk assess-
ment of the compound GHB. The report follows the structure of Annexes A
and B of the risk-assessment guidelines developed by the Scientific
Committee of the EMCDDA.
Pharmacotoxicological evidence
Chemical/pharmaceutical information
Chemical description
Gamma-hydroxybutyric acid (shown below) refers to the protonated form
whereas gamma-hydroxybutyrate refers to the deprotonated form of the car-
boxylic acid moiety. The abbreviation GHB refers to both of these chemical
names. Other chemical names include oxybate, 4-hydroxybutanoic acid,
and 4-hydroxybutyric acid. The chemical structure is shown in Figure 2.
Figure 2: Chemical structure of GHB
The chemical abstracts registration (CAS) number for ‘free’ gamma-hydroxy-
butyric acid (GHB) is [591-81-1] and [502-85-2] for GHB sodium salt
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(7) This report was written by S. P. Elliott of the Regional Laboratory for Toxicology (City
Hospital NHS Trust, Birmingham, United Kingdom) for the risk-assessment meeting on GHB;
Lisbon 25 and 26 September 2000, EMCDDA.
C4H8O3Molecular formula:
Molecular weight: 104.11
(NaGHB). GHB sodium salt is a white solid, soluble in water and methanol.
GHB salts other than sodium can also be formed, for example GHB potassi-
um salt (KGHB).
PRECURSORS
There are various chemical precursors to GHB. Gamma-butyrolactone (GBL)
and 1,4-butanediol have both been found to undergo in vivo conversion to
GHB in animals and humans. The hydrolysis of GBL to GHB is catalysed in
vivo by a lactonase (Roth et al., 1966). In rat whole blood the half-life con-
version of GBL was only 1 minute, with serum more active than plasma
(Roth et al., 1966). Rat liver was also found to have substantial lactonase
activity, however, human cerebrospinal fluid (CSF) did not. It was found that
muscle tissue can sequester a large part of the initial GBL dose, thereby
delaying conversion to GHB and prolonging the duration of action. GHB for-
mation from GBL is chemically a reversible reaction and appears to be pH
dependent. Under acidic conditions, GHB can be converted to the lactone,
GBL, a process that has been exploited for gas chromatographic analysis of
the compound (Vree et al., 1976). No endogenous GBL has been detected in
plasma or urine, therefore, it is assumed that this conversion does not occur
in vivo. It has also been reported that 1,4-butanediol is also rapidly
metabolised to GHB in vivo, in a reaction catalysed by the enzyme alcohol
dehydrogenase (ADH) (Maxwell et al., 1971; Roth et al., 1968).
METHODS OF SYNTHESIS
Illicit GHB is reportedly synthesised using various methods. If pharmaceuti-
cal-grade GHB cannot be obtained, users/producers usually exploit the con-
version of GBL to GHB under certain conditions (e.g. alkaline pH > 7).
Notionally this requires the addition of sodium hydroxide (or potassium
hydroxide) with water to GBL. There are various dangers associated with
such a reaction, particularly as the reaction is exothermic and GBL is flam-
mable. Furthermore, commercially-available domestic or industrial prod-
ucts, which could be used for synthesis, are not meant for human consump-
tion and invariably contain other potentially toxic substances, including
heavy metals and other organic solvents such as acetone or toluene. Use of
such products as reagents may result in serious toxic effects if the resultant
impure product is consumed. To aid the producer, ‘GHB kits’ are available
which apparently contain the necessary ‘pure’ ingredients in ‘accurately
weighed’ amounts. Various ‘recipes’ have been presented both on the
Internet and in books (Ward et al., 1998).
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IDENTIFICATION
The analytical profile of GHB has been described in numerous papers. In
particular, data pertaining to gas chromatography with mass spectrometry
(GC-MS) and gas chromatography with flame ionisation detection (GC-FID)
are described (Vree et al., 1976; McCusker, et al., 1999; Ferrara et al., 1993;
Couper et al., 2000); analysis usually requires conversion to γ-butyrolactone
(GBL) or chemical derivatisation. A chemical (colour reaction) spot test has
been developed which also requires the conversion of GHB to GBL
(Badcock et al., 1999). GHB is not detectable using traditional field-test kits.
Legitimate uses of GHB
GHB has been used in various pre-clinical and clinical trials since 1960.
GHB was originally evaluated as an anaesthetic particularly in France and
Germany (as Gamma OHTM and SomsanitTM, respectively). It has also been
assessed in the treatment of narcolepsy and associated disorders such as cat-
aplexy, in addition to its use as an aid to opiate and alcohol withdrawal in
Italy (as AlcoverTM). There are no known reported industrial uses of GHB,
however, GBL and 1,4-butanediol are used as solvents in various industrial
processes.
Pharmaceutical form
GHB is available as either a liquid formulation or as a powder (either loose
or sometimes in a capsule). It has various street names including ‘liquid
ecstasy’, ‘liquid E’, ‘GBH’, ‘easy lay’, ‘scoop’, ‘liquid X’, ‘fantasy’ and ‘cherry
meth’.
Seized GHB material in Europe appears to consist of both powder and liquid
preparations. Seizures of GBL and 1,4-butanediol are predominantly in liquid
form. The following is a list of some common (mostly previously available)
GHB-related products usually sold as ‘nutritional or dietary supplements’
(http://www.erowid.org).
‘Blue Nitro’ contains GBL, Vitamin B12 and Potassium
‘RenewTrient’ contains GHB  
‘Midnight Blue’ contains GBL
‘SomatoPro’ contains 1,4-butanediol  
‘Serenity’ contains 1,4-butanediol  
‘Enliven’ contains 1,4-butanediol  
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GHB and related products are generally perceived to be cheap to purchase
compared to other illicit drugs, in respect of the cost per effective dose.
Route of administration and dosage
As GHB is invariably obtained in the form of a powder or liquid formulation,
the primary route of administration is oral. However, it does not preclude the
possibility of the powder being ‘snorted’ or ‘smoked’ or the liquid being
injected — although there are no confirmed reports of these routes of admin-
istration. The powder (usually GHB sodium salt) is invariably mixed with
water prior to consumption. Many of the dangers associated with illicit GHB
use are due to variances in the GHB concentrations of such solutions.
Furthermore, the concentration of ‘pre-prepared’ liquid solutions can also
vary considerably. Many web sites and books which advocate GHB use sug-
gest that an individual ‘finds the dose they are comfortable with’ and ‘takes
GHB on an empty stomach for a more rapid effect’ (Ward et al., 1998). This
is due to the fact that GHB appears to ‘effect different people in different
ways’ — a euphoric dose for one person could be a sedative dose for anoth-
er (Kam et al., 1998). The steep dose-response curve of GHB — where a
small increase in the dose can cause sedation as opposed to just nausea —
could also cause problems in terms of the user selecting the required dosage
or taking subsequent doses in quick succession. However, it is generally sug-
gested that a 0.5 g dose be taken for relaxation and disinhibition, a 1 g dose
for euphoric effect and a 2–3 g dose for deep sleep (Ward et al., 1998;
http://www.erowid.org; http://www.lycaeum.org).
Toxicology and pharmacology in animals and humans
Pharmacodynamics and preclinical safety data
NEUROPHARMACOLOGY
GHB was first synthesised in 1960 by Laborit (1964) in an attempt to study
the effects of butyric acid and GABA (γ-aminobutyric acid), producing a
compound which would interfere with β-oxidation and would cross the
blood-brain barrier. Bessman and Fishbein (1963) later discovered that GHB
is an endogenous compound existing as a proposed metabolite of GABA.
During these studies GHB was isolated in the brain of both rats and humans.
Some researchers postulated that GHB was also a putative neurotransmitter
or neuromodulator (Mandel et al., 1987; Cash, 1994).
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There have been many studies detailing the effects of GHB on various neu-
rotransmitter systems, particularly serotonin (5-HT, 5-hydroxytryptamine),
noradrenaline (NA, norepinephrine), dopamine (DA) and acetylcholine
(ACh). Although these studies have produced variable results, the data sug-
gest that GHB does have a significant effect on the dopaminergic system.
There may also be an accompanied increase in the release of endogenous
opioids, for example, dynorphin (Hechler et al., 1991).
Giarman and Schmidt (1963) noted that at relatively high doses of GHB,
ACh levels were increased in certain regions of the brain. Early work by
Gessa et al. (1966) studied the effect of GHB on 5-HT, NA and DA in the
brains of rabbits and Long-Evans rats. Rabbits were injected intravenously
(i.v.) and rats were injected intraperitoneally (i.p.) with varying doses of GHB
ranging from 250 mg/kg to 2 000 mg/kg and sacrificed 0–4 hours post dose.
The results of the various experiments indicated that there is a slight increase
in 5-HT and NA levels in the brain; however, they observed a pronounced
increase in brain DA levels (primarily in the caudate nucleus). The maximal
increase in DA concentration occurred 1–2 hours after administration of
2 000 mg/kg of GHB with a slow decline thereafter. Further study of the
effects of GHB on DA involved the administration of L-DOPA and a known
monoamine oxidase inhibitor (MAOI), pargyline. It was found that although
DOPA produced an initial higher increase in rat brain DA, GHB produced a
more sustained increase and co-administration of the two compounds
(DOPA 50 mg/kg i.v. and GHB 2 000 mg/kg i.p.) produced a further increase.
Furthermore it also appeared that DOPA-decarboxylase was not affected by
GHB. Administration of pargyline (80 mg/kg i.p.) to rats produced complete
monoamine oxidase (MAO) inhibition, whereas MAO activity was not inhib-
ited following a 2 000 mg/kg i.p. GHB dose. It was concluded that GHB
does not appear to be a MAOI.
Other studies concerning GHB and brain DA levels confirmed that DA is
altered in response to GHB (Walters et al., 1973; Bustos et al., 1972; Spano
et al., 1971; Cheramy et al., 1977; Godbout et al., 1995). It appears that
there is an initial inhibition of DA release at the synapse but an increase in
neuronal DA production. After this intracellular increase in DA there is either
a time-dependent (DA increases with time) or dose-dependent non-func-
tional leak of DA from the neurone (low doses inhibit, high doses stimulate).
Both theories ultimately result in a pronounced increase in brain DA con-
centration. However, Feigenbaum and Howard (1996) have reported that
GHB inhibits rather than stimulates DA release and that experiments show-
ing DA stimulation were performed under anaesthesia or in the presence of
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high calcium concentrations; such conditions apparently have been found to
spuriously enhance striatal DA release.
GHB was also found to have an affinity for two receptors in the brain — a
possible GHB-specific receptor and GABAB receptor. GHB appeared to have
no affinity for the GABAA receptor. Evidence for a GHB-specific receptor
came from experiments by Benavides et al. (1982) and Maitre et al. (1990)
involving radiolabelled GHB ((3H)GHB), which bound to the receptor even
in the presence of GABA, and binding inhibition studies using a GHB antag-
onist NCS-382, which prevented GHB binding. The highest concentrations
of the GHB binding sites in rat brain were in the olfactory bulbs, hippocam-
pus and cerebral cortex. Further work using rat brain membranes suggest
that the receptor is linked to the Gi or Go family of proteins (Ratomponirina
et al., 1995). Godbout et al. (1991) reported that there is an increase in spon-
taneous firing in prefrontal cortical neurones after administration of low
doses of GHB. As this is inhibited by NCS-382, it suggests that GHB binding
to the GHB-specific receptor mediates this response. DA is known to inhib-
it prefrontal nerve cells, suggesting that GHB reduces the DA levels, thus
preventing inhibition of prefrontal cortical neuronal firing. GHB inhibits DA
release by binding to the GHB-specific receptor. However, administration of
high doses of GHB produced inhibition of these neurones. It was postulated
that this was due to an increase in DA levels resulting from GHB-induced
stimulation of a second receptor, GABAB (Nissbrandt et al., 1996; Bowey,
1989; Xie et al., 1992; Williams et al., 1995). GHB has been found to be
only a weak agonist of this receptor, exhibiting a binding affinity of 1 000
times less than GABA and 1 000 times less than binding to the GHB-specif-
ic receptor (Mathivet et al., 1997). Studies using a GABAB antagonist, CGP
35348, indicated that GHB activation of the GABAB receptor produces
hyperpolarisation (Williams et al., 1995). A Na+ dependent GHB transport
has also been discovered which is thought to remove GHB from the synap-
tic cleft following neuronal release (Benavides et al., 1982).
NEUROENDOCRINOLOGY
Following an intravenous 2.5 g dose of GHB in six male human volunteers,
a significant increase in both plasma prolactin and growth hormone (GH)
was observed at 30, 45, 60 and 90 minutes post dose (Takahara et al., 1977).
Five of the six patients fell asleep. These effects were not observed in the
saline controlled group. As DA is known to inhibit prolactin production, the
results suggested there was a GHB-induced reduction in DA. However, as
growth hormone secretion is known to be increased by dopaminergic stim-
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ulants, it was concluded that the growth hormone increase in this case was
not due to GHB-inhibition of DA release. Other work had indicated that 5-
HT and a precursor (5-hydroxytryptophan) stimulated prolactin and growth
hormone secretion in rats and humans (Kato et al., 1974; Smythe et al.,
1975). It was therefore speculated that GHB may induce prolactin and
growth hormone release by modifying the release of 5-HT from the nerve ter-
minals. Further postulation suggested that GHB acts directly on neurons in
the hypothalamus and stimulates or blocks the release of GH-releasing or
GH-release inhibiting and prolactin-release inhibiting hormones. The slow-
wave and REM (rapid eye movement) sleep apparently induced by GHB (see
Effects on brain function) is also thought to be the periods of sleep where GH
production is at its greatest (Chin et al., 1992).
CARDIOVASCULAR AND RESPIRATORY EFFECTS AND THERMOREGULATORY RESPONSES
Laborit (1964) observed a constant but short drop in blood pressure in rab-
bits after administration of GHB, but in dogs there was either no effect or a
slight progressive increase in blood pressure (even under controlled ventila-
tion conditions). In all animals, a constant bradycardia was observed. GHB
also appeared to elevate the sensitivity threshold of the pressure receptors in
the rabbit and dog, without having any obvious action on the chemorecep-
tors. Laborit and Leterrier (1964) also observed a strong hepatic and renal
vasodilating action, particularly during haemorrhagic shock in animals, indi-
cating that GHB has ‘antishock activity’. In humans, after a 2–4 g injection
of GHB there appeared to be no effect on blood pressure, unless during
surgery when, in the absence of adequate neuroplegic premedication, a pro-
gressive hypertensive episode occasionally occurred. In addition, there were
no unfavourable effects observed in 50 human atherosclerotic patients under
GHB anaesthesia. However, a frequent decrease in the amplitude of the T-
wave was noted, but this appeared to be due to the hypokalaemia (reduction
in serum potassium levels) associated with GHB (Laborit, 1964). This was
reversed by the administration of potassium. A study in Poland of 100
patients also suggested that administration of GHB resulted in a constant
drop in blood cholesterol levels (Laborit, 1964).
Laborit also observed in both animals and humans that GHB-induced sleep
is not accompanied by a decrease in oxygen consumption. At low hypnotic
doses of GHB, a decrease in ventilatory rate was reported with an increase
in amplitude. At high (sleep-inducing) doses of GHB, a Cheyne-Stokes
rhythm appeared (including periods of apnoea, often observed in coma
patients); however, the respiratory centre remained sensitive to an increase
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in carbon dioxide (pCO2). Both Laborit and Gessa (1966) reported a slight
drop in body temperature of animals given GHB. Gessa noted that this
appeared particularly pronounced in rats receiving 2 g/kg GHB kept at 18 oC
compared to those kept at 37 oC (room temperature).
EFFECTS ON BRAIN FUNCTION
Many researchers have recorded the effects of GHB on brain function in
animals and humans using an electroencephalogram (EEG) (Laborit, 1964;
Winters et al., 1967; Marcus et al., 1967; Scotti et al., 1978; Mamelak et al.,
1977; Metcalf et al., 1966; Entholzner et al., 1995). The results have been
contradictory to some extent, with GHB producing various EEG patterns in
various animal and human models. Some animal studies report apparent
epileptiform (epileptic/seizure-like) EEG changes which have not been
observed in human volunteer studies following GHB administration.
Random clonic movements of the face and extremities have been reported
to be associated with GHB-induced anaesthesia without epileptiform EEG
changes. In fact, Jouany et al. observed that GHB apparently controlled
chemical-induced seizures (using ammonium chloride, strychnine, cardiazol
and isoniazide) to some extent (Laborit, 1964).
Based on behavioural and electroencephalographic criteria, GHB-induced
sleep has been described as being indistinguishable from natural sleep, that
is unlike coma. The natural stages of sleep 1–2–3–4–REM (rapid eye move-
ment) all occur in their normal sequence (Mamelak et al.,1977). GHB has
been noted to lengthen stages 3–4 (delta/slow-wave sleep) followed by REM
sleep. The effect of GHB-enhanced sleep appears to wear off after 3–4 hours
at ‘normal’ doses, with no apparent side effects.
TOXICOLOGY
At present there are no animal or human data concerning reproductive tox-
icity, neurotoxicity or the mutagenicity and carcinogenic potential of GHB.
Toxicity in animals
Laborit (1964) found sleep could be induced in the rat with 0.5 g/kg GHB
(i.p.) and in rabbits and dogs using 1 g/kg (i.v.). In rats, the LD50 (i.p.) was
1.7 g/kg and the LD100 was 2 g/kg. The cause of death was reported to be res-
piratory depression; however, using artificial respiration rabbits tolerated
doses up to 7 g/kg. With respect to weight, bone marrow, liver and kidneys,
there were no significant differences observed between controls and rats
receiving 0.17 g/kg GHB daily for 70 days.
During the course of the various experiments involving the administration of
GHB to animals at numerous doses, the following observations have been
made regarding the toxicity of GHB in animals. The toxicity of GHB appears
to be dose-dependent and can induce various degrees of sleep, bradycardia,
a decrease in body temperature and possible seizures/spasms. Death has
been reported to be due to respiratory depression in rats.
Toxicity in humans
Early reviews concerning the use of GHB, particularly in anaesthesia, sug-
gested that GHB was non-toxic (Laborit, 1964). Short amnesia and hypoto-
nia have been associated with an oral dose of 10 mg/kg GHB (Chine et al.,
1992). REM sleep can be induced in humans using an oral dose of between
20-30 mg/kg GHB (Mamelak et al., 1986; Yamada et al., 1967). 50–70 mg/kg
GHB given intravenously produces hypnosis but has little analgesic effect
(Appleton et al., 1968). This dose may also cause hypotonia, bradycardia,
nausea, vomiting, random clonic movements of the face and extremities and
Cheyne-Stokes respiration (Laborit, 1964; Chin et al., 1992). Following a
typical 65 mg/kg intravenous dose of GHB, sleepiness can occur within
5 minutes, followed by a comatose state lasting for 1–2 hours or more, after
which there is a sudden awakening (Vickers, 1968). High oral doses of GHB
(greater than 60 mg/kg) can also result in coma, usually lasting up to 4 hours
(Mamelak, 1989). Table 1 shows a summary of resultant concentrations fol-
lowing various GHB doses.
Table 1: Reported concentrations of GHB in blood/plasma and urine
In 1964, Helrich et al. reported that blood GHB concentrations exceeding
260 mg/l were associated with deep sleep, 156–260 mg/l associated with
moderate sleep, 52–156 mg/l associated with light sleep and levels less than
52 mg/l were associated with wakefulness.
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Dose Effect(s) GHB concentration Reference
25 mg/kg (oral) Drowsiness 80 mg/l (peak plasma) Palatini et al., 1993
75 mg/kg (oral) Sleep 90 mg/l (peak plasma) 2 hours Hoes et al., 1980
9 mg/l (plasma) 6 hours
50 mg/kg (i.v.) 170 mg/l (peak blood) Helrich et al., 1964
100 mg/kg (oral) 1 100 mg/l (peak urine) Hoes et al., 1980 
in 4 hours 
Interactions with other drugs or medicines
There have been various published reports of GHB intoxication, however,
the frequent presence of other drugs may have complicated the clinical pre-
sentation. Typical presentation appears to be various degrees of conscious-
ness, euphoria (‘high’), aggressive behaviour, ataxia, amnesia, somnolence,
bradycardia, confusion, hallucinations, respiratory depression and apnoea,
vomiting and random clonic movements (sometimes reported as being
seizures) (Kam et al., 1998; Chine et al., 1998; Li et al., 1998a; Li et al.,
1998b). Presenting patients have been reported to have initial GCS scores
(Glasgow coma score) of between 3 (severe decrease in consciousness) and
15 (wakeful) (Chin et al., 1998; Williams et al., 1998). There have been no
detailed studies concerning the interaction of GHB with other drugs or med-
icines. However, it is believed the adverse effects of GHB intoxication are
exacerbated by the presence of other sedatives or depressants such as opi-
ates (e.g. heroin or morphine), benzodiazepines, barbiturates or alcohol (e.g.
ethanol) and possibly other psychoactive compounds (e.g. amphetamine).
Depending on the nature of the interaction, resultant effects may also
depend on the order in which the drugs are administered — for example,
there may be potential problems if amphetamine is ingested after GHB due
to the resultant release of neuronal dopamine.
Various possible reversal/antagonizing agents have been tested against the
clinical effects of GHB toxicity. Commonly used coma reversal agents such
as naloxone (opiate/opioid antagonist) and flumazenil (GABA, benzodi-
azepine antagonist) had no effect (Mamelak et al., 1986; Yamada et al.,
1967; Vickers, 1968). In addition, various anticonvulsant and other agents
have been tested using animal models (e.g. ethosuximide, sodium valproate,
clonazepam, diazepam, L-dopa, phenobarbitone); however, although there
were some EEG changes, the results appeared to be species specific
(Mamelak et al., 1986). An investigation by Henderson et al. (1976) showed
that intravenous physostigmine was effective in reversing the anaesthetic
action of GHB in 25 patients. These results were confirmed by Schöntrube
et al. in 1993. Due to the rapid gastro-intestinal absorption of GHB, gastric
lavage and administration of activated charcoal are of limited use. Treatment
of GHB intoxication is therefore largely supportive and intubation with
mechanical ventilation is sometimes used (particularly to protect the airway
if the patient is vomiting) (Appleton and Burn, 1968). However, in the major-
ity of cases the patient awakes spontaneously within approximately 7 hours
(presumed to be due to the short elimination half-life of GHB).
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Cases of GHB intoxication in humans
Non-fatal cases
As GHB is not usually detected during routine toxicological analysis
(Badcock and Zotti, 1999; Williams, 1998; Elliott, 2000) the evidence for
GHB or related product ingestion (e.g. GBL or 1,4-butanediol) is usually
based on anecdotal or circumstantial evidence.
There have been many reported cases of intoxication linked to GHB, how-
ever, there also appear to be many more unconfirmed/anecdotal reports
(http://www.erowid.org; http://www.lycaeum.org). There have been other
reports of toxicity resulting from ingestion of GBL or 1,4-butanediol; the
patients presented with identical symptoms to cases involving GHB inges-
tion (CDC, 1999; Dyer et al., 1997; Rambourg-Schepens et al., 1997). This
is consistent with the reported in vivo conversion of these compounds to
GHB (Poldrugo and Snead, 1984; Lettieri and Fund, 1978).
The majority of reported cases have occurred in the United States (Couper
and Logan, 2000; Chin et al., 1992; Chin et al., 1998; Li et al., 1998; Stokes
and Woekener, 1998; CDC, 1999; CDC, 1997; FDA, 1990; FDA, 1997;
CDC, 1990; CDC, 1997; Dyer et al. 1991; Steele and Watson, 1995; Dyer,
1991; Viera and Yates, 1999; Eckstein et al., 1999) and Europe
(http://erowid.org; Williams et al., 1998; EMCDDA; Elliott, 2000; Kouagie et
al., 1997; Vandevenne et al., 2000; Hovda et al., 1998; Personne and
Landgren, 2000; Knudsen, 2000; Hunderup and Jorgensen, 1999) although
abuse of GHB has also been reported in Australia (Australian Drug
Foundation). Based on documented cases and reports to Reitox national
focal points, it can be estimated that there have been at least 200 presumed
GHB overdose cases in Europe (EMCDDA); global estimates range from hun-
dreds to thousands of cases (CDC, 1997a; FDA, 1990; FDA, 1997; CDC,
1990; CDC, 1997b). In Sweden and the United Kingdom alone, there have
been at least 100 apparent GHB-related hospital admissions since 1996.
Eight cases have been reported in the Netherlands, 12 cases in Denmark,
two cases in Belgium, two cases in Finland, three cases in Norway and one
case in Spain (EMCDDA).
Williams et al. (1998) reported six cases of probable GHB intoxication
occurring between 1995 and 1996 in London, United Kingdom. These cases
are summarised in Table 2. The clinical observations in these cases confirm
those of other cases where it appears that patients present in various states
ranging from initial confusion, dizziness or euphoria, leading to collapse,
vomiting and loss of consciousness/coma (Chin et al., 1992; Chin et al.,
1998; Li et al., 1998; Li et al. 1991; Dyer et al., 1991; Steele and Watson,
1995; Dyer, 1991; Viera and Yates, 1999; Eckstein et al., 1999).
Administration of naloxone and flumazenil did not appear to have a signifi-
cant effect and in the majority of cases activated charcoal was administered
and the patient was intubated. All patients eventually recovered and were
either discharged or self-discharged. The reported ‘dose’ of GHB varied,
however the true amount/concentration of GHB ingested was unknown, as
the exact composition of the GHB product was not usually
ascertained/analysed. Furthermore, in these particular cases it was not
known/confirmed if other drugs were ingested which may have exacerbated
the effects; however, the co-ingestion of alcohol (ethanol) was frequently
mentioned.
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Case Patient Reference and Clinical presentation Comments
No details country of 
occurrence
1 32 yr M Williams et al., Collapsed, unconscious, dilated pupils. Unknown dose. Reported 
1998 GCS 8, BP 100/60, pulse 70 bpm.  to have also taken MDMA, 
(United Discharged 2 hours after arrival. cannabis, ethanol and 
Kingdom) amyl nitrite.
2 28 yr M Williams et al., Collapsed, unconscious. GCS 3, One capsule of GHB at 
1998 BP 100/60, pulse 90 bpm. Naloxone nightclub. Reported to 
(United given — no effect. Discharged have also taken MDMA.
Kingdom)    10 hours after arrival.
3 29 yr F Williams et al., Collapsed, unconscious, dilated pupils. Half a bottle of GHB at 
1998 (United BP 80/60, pulse 50 bpm. Discharged nightclub. No other drugs 
Kingdom) 1.5 hours after arrival. or ethanol reportedly 
ingested.
4 20 yr M Williams et al., Collapsed, naloxone given at scene — Unknown dose. Heroin 
1998 (United some recovery. In hospital — decreased user, reported to have 
Kingdom) level of consciousness. BP 135/70, pulse taken methadone then 
60 bpm. Discharged following morning GHB to aid opiate 
(approximately 6 hours after arrival). withdrawal.
5 25 yr M Williams et al., Collapsed, unconscious. GCS 3, Unknown dose. 
1998 (United BP 82/50, pulse 56 bpm. Naloxone Bodybuilder, GHB pow-
Kingdom) given — no effect. Discharged 4 hours der dissolved in drink 
after arrival. with 2 pints of lager.
6 20 yr M Williams et al., Collapsed, unconscious. GCS 3, Unknown dose. First use 
1998 (United BP 110/45, pulse 74 bpm. Naloxone of GHB, powder dis-
Kingdom) given — no effect. Discharged 5 hours solved in drink with a 
after arrival. large amount of alcohol.
Table 2: Six cases of United Kingdom reported hospital admissions
implicating GHB ingestion and toxicity
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In some cases, however, extensive drug screening has been performed and
the presence of GHB has been confirmed and the concentration mea-
sured/estimated in biological fluid (Couper and Logan, 2000; Elliott, 2000;
Louagie et al., 1997; Vandevenne et al., 2000, le Gatt et al., 1999; Baselt,
2000; Dyer et al., 1994). A selection of these cases is presented in Table 3.
Fatal cases
Approximately 65 deaths in the United States have been linked to GHB since
1990 (FDA, 1997a). In Europe, approximately 11 deaths in which GHB has
been implicated have been reported since 1995. United Kingdom (four deaths
— September 1995, March 1996, November 1997 and January 1999),
Sweden (four deaths — February 1996, March 1997, 1998–2000), Finland 
(two deaths — 1998 and 1999) and Denmark (one death — January 2000)
(http://www.erowid.org; http://www.lycaeum.org; EMCDDA; Elliott, 2000).
However, recently there have been a further two unconfirmed cases in the
United Kingdom and one case in Sweden (EMCDDA; Mixmag, 2000). Table 4
shows reported cases involving GHB or GBL ingestion. Due to in vivo con-
version of GBL to GHB, only GHB is usually detected in biological fluids
analysed in such cases. The majority of cases have involved the ‘recreation-
al’ abuse of GHB for its apparent euphoric or ‘high’ effects, primarily by
young people.
Case Patient Reference and Drugs detected GHB Comments
No details country of concentration
occurrence
1 13 yr M Elliott, 2000a GHB Serum > 100 mg/l At school
(United Kingdom)
2 33 yr M Elliott, 2000a  GHB + morphine Urine/serum Heroin user
(United Kingdom) + 6-MAM > 100 mg/l
3 32 yr M Elliott, 2000a GHB + MDMA Urine/serum 
(United Kingdom) + amphetamine > 100 mg/l
4 44 yr M Elliott, 2000a GHB + MDMA Urine/serum Nightclub
(United Kingdom) + cocaine > 50 mg/l
5 23 yr M Vandevenne, GHB + MDMA + Urine = 34 mg/l Ingested an ‘unknown’
2000 (Belgium) cocaine + Serum = 133 mg/l clear liquid, found to 
amphetamine (no be GBL
ethanol detected)
6 F Louagie, 1997 GHB + ethanol Serum = 125 mg/l Party
(Belgium) (134 mg/dl)
Table 3: Collection of confirmed hospital admissions involving 
GHB ingestion and toxicity
Table 4: Collection of reported fatalities involving 
GHB ingestion and toxicity
There are certain factors that should be noted in GHB cases:
 The presence of other drugs (particularly alcohol and opiates/opioids e.g.
heroin, codeine, methadone and morphine).
 Some researchers describe the presence of GHB in post mortem blood
specimens, in cases where there has been no evidence of GHB.
 The GHB concentration found is sometimes low.
The mode of abuse of GHB frequently involves the use of other drugs such
as alcohol or MDMA, therefore, deaths involving solely GHB appear to be
rare. The presence of alcohol and other depressant drugs is widely believed
to exacerbate the toxic effects of GHB ingestion. Therefore, the presence of
such drugs in deaths involving GHB should be taken into consideration
when assessing fatalities attributed to GHB intoxication. Ferrara et al. (1995)
reported a death involving GHB and heroin (diacetylmorphine). A high con-
centration of morphine was detected in the blood (770 mg/l). In most of the
other reported GHB deaths, ethanol has also been involved at significant
concentrations (EMCDDA; Hale; Davis, 1999). In the United Kingdom case
in 1995 involving both GHB and ethanol, the mechanism of death was stated
to be respiratory depression (Hale).
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Case Patient Reference Drugs detected Concentration(s) Comments
No details
1 42 yr M Ferrara et al. GHB + morphine Blood GHB = 12 mg/l Heroin user, used 
(Italy, 1993) + 6-MAM (1) Urine GHB = 258 mg/l GHB (AlcoverTM).
Blood morphine = 770 g/l
Blood 6-MAM = 29 g/l
2 21 yr F Hale (United GHB + ethanol Blood GHB = 356 mg/l At a party ingested 
Kingdom, 1995) Blood ethanol = 47 mg/dl GHB product  
‘Seventh Heaven’.
3 31 yr F Erowid and GHB 
EMCDDA + ephedrine 
(Sweden, 1996) + ethanol
4 31 yr M Erowid and GHB + ethanol
EMCDDA
(Sweden, 1997)
5 17 yr F EMCDDA GHB + ?
(Finland, 1998)
(1) 6-MAM = 6-monoacetylmorphine (heroin metabolite)
Recently, several researchers have reported that GHB was present in signifi-
cant concentrations in post mortem blood, even in cases where the dece-
dents had died in circumstances apparently unrelated to GHB (Fieler et al.,
1998; Anderson and Kuhwahara, 1997; Stephens et al., 1999). In 1998,
Fieler, Coleman and Baselt detected GHB in 15 out of the 20 post mortem
blood specimens analysed. The apparent concentrations ranged from
3.2–168 mg/l (average = 25 mg/l) using GC-MS analysis. Subsequent
reanalysis using GC-FID confirmed these findings. No GHB was detected in
the blood or urine of living patients, in addition, no GHB was detected in
eight post mortem urine specimens analysed. They suggested that GHB is a
product of post mortem decomposition. Further work by Stephens, Coleman
and Baselt was published in 1999 indicating that certain storage conditions
could elevate the concentration of GHB in post mortem blood samples;
namely if the sample was stored in a non-fluoridated container above 4°C.
Again, they found concentrations within the range (9–433 mg/l) in post
mortem blood (average = 57 mg/l) and only detected GHB in 3 out of 17
post mortem urine specimens. If confirmed by further studies this phenome-
non has profound implications for the interpretation of post mortem GHB
concentrations.
In the majority of GHB-related deaths the concentration in post mortem
blood has been found to be ‘high’, however in several cases the concentra-
tion was found to be relatively low, e.g. less than 50 mg/l. Such concentra-
tions are within the range of GHB concentrations apparently produced post
mortem, as stated above. Furthermore, in living persons, similar concentra-
tions have been detected in unconscious patients who awake a few hours
later with no obvious side effects. Due to the rapid absorption and metabo-
lism of GHB, however, it is difficult to predict how much of the original dose
such post mortem concentrations represent.
In conclusion, more research and thorough analysis of GHB in fatalities and
poisonings is still required before the true involvement of GHB can be estab-
lished and accurate mortality and morbidity figures produced.
PHARMACOKINETICS
In 1969, Roth and Giarman demonstrated that [3H]GABA is converted to
[3H]GHB via succinic semialdehyde (intermediate compound) in brain tis-
sue. This was later confirmed by Anderson et al. (1977). The conversion is
catalysed by the enzymes; GABA aminotransferase and succinic semialde-
hyde reductase (Figure 3).
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Figure 3: Proposed biochemical pathway of 
GHB synthesis and metabolism
Succinic semialdehyde reductase has been found to be different between
species; in human and pig brain the enzyme is dimeric (MR between 82 000
and 110 000 Da), whereas it exists as a monomeric protein in rat and bovine
brain tissue. The enzyme has also been isolated in the mitochondria and as
the substrate for succinic semialdehyde is synthesised in mitochondria, it has
been postulated that the mitochondrion is the site of GHB synthesis, with
subsequent transport to the cytosol. As previously mentioned, GHB can also
be produced after administration of γ-butyrolactone (GBL) or 1,4-butanediol.
GHB is purported to be metabolised via succinic acid and the citric acid
cycle (TCA cycle/Krebs cycle), ultimately producing carbon dioxide and
water. GHB conversion to succinic semialdehyde can be catalysed by
cytosolic GHB-dehydrogenase (accounts for majority of GHB metabolism in
the young animal foetus) or mitochondrial GHB-ketoacidtranshydrogenase
(responsible for majority of GHB metabolism in adult animals) (Kaufman et
al., 1979; Nelson and Kaufman, 1994). Although GHB has the potential to
produce GABA, this was not observed after injecting mice with radiolabelled
GHB (De Feudis and Collier, 1976). Laborit (1964) also postulated that GHB
‘orientated’ glucose-6-phosphate (G6P) into the pentose phosphate pathway
(produces ribose for nucleic acid synthesis and NADPH).
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GHB
GABA
GBL
succinic semialdehyde
Enzymes:
1 GABA aminotransferase
2 succinic semialdehyde reductase
3 GHB dehydrogenase/GHB-ketoacid transhydrogenase
4 succinic semialdehyde dehydrogenase
In humans, GHB is rapidly absorbed, with peak plasma concentrations (Cmax)
occurring within 20–60 minutes post oral dose (tmax = 20–60 min.). This is
consistent with the onset of effects occurring approximately 15 minutes after
an oral dose and can last for up to seven hours, depending on the dose
(Galloway et al., 1997). Effects of intravenous dosage have been reported to
occur within minutes, post administration (Takahara et al., 1977). Following
a 12.5 mg/kg dose, the half-life was 20 minutes (Vickers, 1969). Only 2–5 %
is eliminated as unchanged drug in urine (Laborit, 1964; Hoes et al., 1980).
Clinical experience
Clinical safety data
Preclinical studies
 Laborit (1964) observed that in women in labour, GHB had a ‘spectacular
action on the dilation of the cervix’, an effect which was apparently inde-
pendent of the anti-anxiety and reduced consciousness obtained.
Furthermore, in 1962, Barrier reported that GHB was beneficial in obstetric
surgery due to the absence of respiratory depression in the infant and its
anti-shock property against possible cardiac anoxia (Laborit, 1964).
 Several researchers have observed an anti-anxiety effect of GHB. This was
reported in a preliminary study by Danon-Boileau et al. in 1962, involving
schizophrenic patients. 500 mg of GHB four times a day produced a tem-
porary ‘disinhibiting effect’ and relaxed the patients (Laborit, 1964).
However, a large proportion of reports regarding GHB’s anti-anxiety
effects appear to remain anecdotal.
 In 1972, Laborit remarked on GHB’s ‘aphrodisiac’ actions in humans.
There have been many anecdotal reports which suggest that GHB has four
sexual enhancing effects; disinhibition (e.g. relaxation), heightened sense
of touch, enhancement of male erectile capacity and increased intensity of
orgasm.
 The clinical evidence pertaining to GHB’s possible antidepressant effects
are largely anecdotal. However, Laborit (1964) suggested that the increase
of acetylcholine and dopamine levels in the brain and the apparent
increase in cerebral protein synthesis, serotonin turnover and aspartic acid
levels by GHB, may correct metabolic disturbances secondary to depres-
sive states.
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Clinical studies
GHB AS AN ANAESTHETIC AGENT
In the 1960s, early work involving GHB assessed its potential as an anaes-
thetic agent (Laborit, 1964; Appleton and Burn, 1968; Vickers, 1969).
Anaesthetic doses within the range 60–70 mg/kg were given intravenously to
a patient. GHB has been reported to be involved in over 6 000 cases in gen-
eral anaesthesia, and Laborit noted various advantages compared to other
general anaesthetics, including: non-hypotensive bradycardia, muscle relax-
ant properties, absence of respiratory depression while the response of the
respiratory centre to CO2 is maintained, anti-shock activity, allows easy
induction and maintenance of hypothermia, no venous irritation and appar-
ent low toxicity. However, various disadvantages have also been noted
including: lowers serum potassium levels, duration of action is too unpre-
dictable, only produces complete general anaesthesia in children and poor
pain control. The autonomic nervous system remains active — therefore, as
for other anaesthetics, administration of other agents are required such as
opioid analgesics. Mainly because of the unpredictable duration of action,
GHB was nearly displaced as an anaesthetic agent. However, owing to the
rapid metabolism of GHB and the reliable induction of sedation and anaes-
thesia without depressing either respiratory or cardiocirculatory parameters
or liver and kidney function, GHB is being re-evaluated as an agent in emer-
gency and critical care medicine, mainly in long-term sedation of patients
(Diedrich et al., 1996; Kleinschmidt et al., 1995; Pichlmeier and Schneck,
1991; Pospiech and Schmidt, 1993).
USE OF GHB IN THE TREATMENT OF NARCOLEPSY AND ASSOCIATED CATAPLEXY
Various researchers have studied the use of GHB as a potential treatment for
narcolepsy (Mamelak et al., 1986; Broughton and Mamelak, 1979; Scarf et
al., 1985; Scrima et al., 1990; Delay et al., 1993) due to its sleep-inducing
properties. It was thought that in narcoleptic patients GHB would act to ‘nor-
malise’ sleep patterns and reduce the problems associated with the disorder
such as cataplexy (sudden loss of muscle tone), sleep paralysis, daytime-
drowsiness and hypnagogic events (hallucinations that occur at the onset of
sleep). Mamelak obtained clinical data on 48 narcoleptic patients who had
been treated with GHB for up to 9 years. As GHB-induced sleep wears off
after about 3–4 hours post dose, patients took 2.25–3.0 g of GHB two or
three times a night (i.e. upon waking) (Mamelak et al., 1986). Within the first
few weeks of treatment, many of the patients reportedly felt more alert dur-
ing the day and there was a reduction in hallucinations, cataplexy and sleep
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paralysis (although this did intensify on the first or second night). Symptoms
appeared to intensify during periods of stress, however, few adverse effects
were observed. A degree of weight loss was also reported in some obese
patients. Daytime-drowsiness continued to occur in many of the patients and
some were prescribed stimulants in the morning such as ‘Dexedrine’ (d-
amphetamine) as part of their treatment regimen, in order to achieve the
optimal levels of sleep at night and wakefulness during the day. Other studies
noted the occurrence of intermittent episodes of sleepwalking in some GHB-
treated patients and if sleep is resisted the patient may become confused and
emotionally labile (Mamelak et al., 1986; Scarf et al., 1985).
USE OF GHB IN ALCOHOL AND OPIATE WITHDRAWAL
The use of GHB in alcohol withdrawal has been investigated by various
researchers. In 1989, Fadda et al. treated alcohol-addicted rats with either
GHB (at various doses), ethanol or a placebo, 8 hours after the last dose of
alcohol. The degree of withdrawal tremor was observed. It was found that
GHB appeared to reduce the tremor over a 2-hour period. Gallimberti et al.
(1989) assessed the effectiveness of a solution of GHB (AlcoverTM) in 23 alco-
holic humans. One group received 50 mg/kg of GHB and the other group
received a similar tasting placebo. A withdrawal symptom score was
obtained at baseline and 1–7 hours after treatment. The score was based on
the occurrence of tremors, sweating, nausea, depression, anxiety and rest-
lessness. It was found that GHB-treated patients had a significantly consis-
tent reduced withdrawal score, post treatment, compared to the placebo
control group. These results appeared to support those observed in rats. In
an additional study involving 82 patients, Gallimberti et al. (1992) showed
that GHB was effective in reducing alcohol consumption and craving for
alcohol. However, no long-term outcome was evaluated.
Further evidence for the effectiveness of GHB in the treatment of alcohol
withdrawal syndrome has involved randomised, controlled clinical studies
to compare GHB with well established benzodiazepines. In one single blind
study involving 60 alcoholic patients, an oral dose of 50 mg/kg GHB was
compared with 0.5–0.75 mg/kg diazepam for 10 days (Addolorato, 1999).
No significant difference in the overall efficacy was observed. A second
study involving 43 alcoholic patients, compared an intravenous GHB dose
(50 mg/kg then continued by 10–20 mg/kg/h per infusion) against intra-
venous flunitrazepam (0.2–2 mg bolus continued by 0.015–0.08 mg/kg/h)
for up to 30 days in intensive care patients (Lenzenhuber et al., 1999). If
necessary, clonidine and haloperidol were administered to treat autonomic
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signs of withdrawal and hallucinations, respectively. Again, no difference in
overall efficacy was observed between the two compounds. However, GHB-
treated patients required significantly higher haloperidol (possibly due to
hallucinogenic properties of GHB) and lower doses of clonidine.
In 1993, Gallimberti et al. treated 27 heroin and methadone-dependent
patients with 25 mg/kg of GHB. All patients were in withdrawal and an addi-
tional 14 patients were used as placebo controls. A similar withdrawal score
to that used for the alcohol study was obtained up to 3 hours after treatment
and finally assessed on the eighth day of treatment, before and after admin-
istration of naloxone. The results showed that GHB was effective in reduc-
ing all the signs of opiate withdrawal symptoms, except for diarrhoea and
insomnia, over the 8 days. Although three methadone-dependent subjects
and two heroin-dependent subjects reported transient dizziness or vertigo on
the second/third day, no other side effects were attributable to the adminis-
tration of GHB. One limitation of the use of GHB for withdrawal was noted
to be its short duration of action, as frequent doses of GHB would be
required.
Non-clinical use of GHB (including subjective effects in humans)
It appears that GHB or related products (e.g. GBL and 1,4-butanediol) are
used by various groups of people. The use and abuse of GHB has increased
since 1990 and has been accompanied by an increased presence of GHB-
related web sites on the Internet.
 Bodybuilders exploit the possible growth hormone promoting properties of
GHB in an attempt to increase muscle mass. GHB is therefore illicitly
sold/distributed in gymnasiums or advertised on the Internet or related
web sites. Some people therefore erroneously refer to GHB as an anabol-
ic steroid, which is not the case, as its chemical structure does not resem-
ble a steroid.
 Other people sometimes use GHB as an apparent appetite suppressant or
weight loss product, although there is very little definite scientific data to
support these claims.
 Due to GHB’s sleep-inducing effects, various people suffering sleep disor-
ders such as insomnia or narcolepsy use GHB products in an attempt to
normalise their sleep patterns.
 Some groups have actively promoted (again usually via the Internet) the
potential anti-ageing effects of GHB due to claimed indirect anti-oxidant
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properties of the compound by stimulating the glial cell pentose phosphate
pathway producing NADPH for the reduction of oxidised glutathione
(South, http://www.smartdrugs.com).
 GHB is also used as a sexual adjunct to enhance libido and sexual func-
tion, by both heterosexuals and homosexuals. Therefore, various GHB or
related preparations are also sold in ‘sex shops’.
 The apparent primary mode of abuse worldwide has been the use of GHB
for its subjective hypnotic, euphoric and hallucinogenic properties.
Although some users reportedly use GHB ‘to relax’ and may use it as an
alternative to alcohol, many users attempt to attain a desired ‘high’, simi-
lar to that sought from ‘ecstasy’ (e.g. MDMA). Hence, liquid GHB is some-
times referred to as ‘liquid ecstasy’, ‘liquid X’ or ‘liquid E’, although the
mode of action and chemical structure of MDMA and GHB are consider-
ably different. GHB has been found to be associated with social gatherings
such as parties, nightclubs, music events (e.g. ‘raves’ or festivals), drinking
establishments, etc. In such situations there is the danger of concomitant
ingestion of other drugs or alcohol, which will potentiate the effects of
GHB. The majority of reported hospital admissions and deaths have been
related to such instances of abuse.
 Recently, there has been the suggestion that GHB has allegedly been used
for illicit sexual activity or ‘date rape’, due to the potential incapacitating
and sleep-inducing effects of GHB (and GBL or 1,4-butanediol) (Smith,
1999; Sohley and Salamone, 1999). As GHB is colourless and easily dis-
solves/mixes in aqueous solutions (e.g. water and other liquids), it can be
surreptitiously introduced into beverages. The required dosage to cause
such effects, however, may require the introduction of possibly large
noticeable quantities of GHB powder or liquid depending on the formula-
tion and purity of the GHB used. Furthermore, if GHB sodium salt or solu-
tion is used, a slight salty taste may be noticeable, particularly if intro-
duced into a previously tasteless liquid such as water (Ward et al., 1998).
Despite this, the use of GHB in such illicit activity is a contentious area of
GHB abuse, as unfortunately it is usually difficult to prove, given the rapid-
ity of GHB metabolism and elimination.
Dependence potential in humans
Dependence potential
There have been few studies regarding the dependence/abuse potential of
GHB. However, during the numerous studies involving administration of
GHB to patients at varying concentrations, no dependence has been
observed at low doses of GHB. At prolonged high doses, however, physical
dependence as evidenced by a withdrawal syndrome has been noted in
some cases and includes symptoms of insomnia, muscular cramping, tremor
and anxiety (Galloway et al., 1997).
Further studies indicated that GHB maintained self-administration marginally
above saline and water (in monkeys and rats, respectively) (Colombo et al.,
1995). Studies of the reinforcing and discriminative stimulus effects of GHB
in monkeys and rats have indicated that GHB was partly substituted for by
morphine, LSD, chlordiazepoxide and GABA-mimetics such as muscimol,
GBL, baclofen and 3-aminopropane sulfonic acid in rats (Winter, 1981).
GHB did not appear to substitute for d-amphetamine, pentobarbital,
diazepam and triazolam in rhesus monkeys (Woolverton et al., 1999).
Woolverton et al. (1999) concluded that GHB has, at most, a low abuse
potential.
Psychological risk assessment (cognition, mood and mental
functioning)
Acute and chronic effects
In general, there are few published data concerning specific psychological
effects of GHB either acutely or chronically. However, recently, Ferrara et al.
(1999) studied the effects of single dose GHB on psychomotor performance
and monitored the patients’ subjective feelings. GHB at doses of 12.5 mg per kg
and 25 mg per kg, including placebos were given to six male and six female
volunteers. The subjects’ psychomotor performance was evaluated at base-
line and at 15, 60, 120 and 180 minutes post dose using critical flicker
fusion, response competition test, critical tracking task, choice reaction time
and visual vigilance task. The subjects’ mood was assessed before and
120 minutes after treatment using 16 visual analogue scales. The results indi-
cated that GHB at either dose had no effect on vigilance, attention, alertness,
short-term memory or psychomotor coordination. Calmness increased at the
lower dose and the subjects apparently felt more contented at both dose reg-
imens. Observed adverse effects consisted of subjective dizziness and dull-
ness but these feelings disappeared 30–60 minutes after administration.
Various observations made in studies involving the administration of GHB to
patients include relaxation, nausea, agitation and sedation/coma (London
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Toxicology Group; Takahara et al., 1977; Chin et al., 1992; Mamelak et al.,
1986; Vickers, 1969). No long-term effects have been reported. After awak-
ening patients are usually alert and feel ‘refreshed’, however, there have
been some reported instances of transient mental disturbance (Steel, 1968).
Galloway et al. (1997) reported that one patient using GHB (dose unknown)
described effects similar to those experienced after alcohol ingestion and
also that it impaired his ability to drive. Two cases have been reported where
GHB has been detected in the blood and urine of drivers. In one case the
driver was found asleep at the wheel after stopping in a traffic lane (Stephens
and Baselt, 1994) and a second driver involved in a road traffic accident was
reported to be confused, combative and delirious (Baselt, 2000).
Other researchers have evaluated the effect of GHB in the treatment of schiz-
ophrenia as it was thought that GHB-induced inhibition of dopamine neu-
ronal firing would be beneficial to afflicted individuals. Levy et al. (1983)
and Schulz et al. (1981) in two separate studies generally did not observe
any significant antipsychotic efficacy of GHB.
Conclusions
 GHB is not a new synthetic drug. It was synthesised in 1960 by Laborit but
was later found to be a naturally occurring compound in mammalian brain
and other tissues.
 Evidence relating to the activity of GHB on neurotransmitter systems is
largely contradictory, however, it appears that GHB is a hyperpolarising
compound that blocks dopamine release at the synapse and produces an
increase in intracellular (neuronal) dopamine.
 GHB has been reported to produce enhanced slow-wave/delta sleep with-
out a decrease in oxygen consumption while the respiratory centre
remains sensitive to carbon dioxide. It also induces anaesthesia but does
not provide pain relief. An increase in growth hormone and prolactin
release has been reported in one study of six human subjects.
 GHB can cross the blood-brain barrier and can be produced in vivo as a
product of GABA metabolism and after administration of GBL (γ-butyro-
lactone) or 1,4-butanediol. GHB is rapidly absorbed and metabolised,
possessing a plasma half-life of approximately 20 minutes and has a steep
dose-response curve. Following an oral dose, effects usually occur after
15 minutes and can last up to seven hours, depending on the dose.
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 GHB has been evaluated for various potential therapeutic uses including
obstetrics, anaesthesia, alcohol/opiate withdrawal and treatment of nar-
colepsy and cataplexy.
 Reports indicate that GHB is used for various reasons and by various sec-
tions of society. These include: its sexual enhancing effects, growth hor-
mone promoting effects (e.g. apparently increasing muscle bulk), relax-
ation and antidepressant effects, postulated anti-ageing properties and
more recently its apparent euphoric (‘high’) effects. There have also been
reports of GHB allegedly being used in cases of so-called ‘date rape’.
 There is limited published data concerning specific psychological effects
of GHB either acutely or chronically, therefore the exact effect of GHB on
cognition, mood and psychomotor ability is unclear.
 Animal and human studies indicate that GHB toxicity is dose-dependent
and can result in coma, random clonic movements, decrease in body tem-
perature, hypotonia, nausea, vomiting, bradycardia, respiratory depression
and apnoea. A possible physical dependence has been observed at pro-
longed high dosage.
 Other depressant or sedative drugs (e.g. opiates, benzodiazepines, alcohol
and barbiturates) and possibly other psychoactive compounds (e.g.
amphetamine) may exacerbate the effects of GHB.
 In humans, non-fatal instances of intoxication and also deaths implicating
GHB have been reported.
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Sociological and criminological (Europol)
evidence on the risks of GHB
Introduction
GHB was developed in the early 1960s as a human anaesthetic but medical
use was limited due to unwanted side effects. Its non-medical use as a sleep
aid and bodybuilding supplement in the 1980s, and as a recreational psy-
choactive drug in the 1990s lead to growing concerns and GHB has been
scheduled in the United States and in some European Member States. This
report summarises the relevant data required by the Technical Annex C of
the Guidelines for the risk assessment of new synthetic drugs. In the absence
of systematic studies of illicit use of GHB, the sociological and criminological
evidence for this report is based on limited information collected from:
 the Reitox national focal points in the 15 EU Member States (1);
 Europol’s contribution to the risk assessment of GHB (2);
 EMEA’s contribution to the risk assessment of GHB (3);
 the Qualitative European Drugs Network (QED) (4);
 the literature (5);
 key European forensic scientists (6);
 key toxicologists in the United Kingdom (7);
 telephone interviews with key experts in the field of recreational drugs (8);
 the Internet (English-language searches) (9); and
 youth and mass media (English-language searches) (10).
Table 5 presents the topics covered in this annex by briefly indicating the
extent and type of evidence that is available. The numbers as in the list
above are used in the table to code the sources of information. Where infor-
mation is available, it is presented and examined under the main category
headings. In general, there is insufficient information, or too much overlap,
to address each of the subheadings in the text.
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Table 5: Sociological and criminological evidence for GHB
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Topics Recorded evidence (see text for details)
Social consequences for the user Mainly related to the steep dose-response curve and unpredictable
dose resulting in loss of physical control and consciousness and to
the ingestion of caustic soda. (6, 7, 9, 10)
Primary relations and/or family No evidence but legal sanctions may result in criminal records, 
problems distress and stigma for the users and their families, etc. (5, 8)
Education and employment No evidence but legal sanctions may result in users being dismissed 
problems from work or education. GHB also offers an opportunity for 
inebriation without detection to people who are undergoing drug or 
alcohol treatments or monitoring. (8,9)
Marginalisation Mainly related to legal controls and sanctions which vary depending
on the countries and the sanctions applied. (1, 4, 5, 8, 9)
Consequences on the social As above.
behaviour of the user
Drug-related disorderly conduct Anecdotal evidence of clumsy behaviour, vomiting and loss of
consciousness in dance settings which is regarded unfavourably by
music promoters, club owners and youth media journalists. (8, 10)
Drug-related acquisitive crime No evidence.
Drug-related violence Reports on the use of GHB for drug-assisted sexual assault. (5, 6, 9, 10)
Drug-related traffic offences High potential for accidents. (6, 7, 8, 9)
Other social consequences The ease with which GHB can be acquired, or manufactured,
allows more consumer power than that usually found in illicit drug
markets in the EU. (8, 9) 
The use of GHB to induce relaxation and sleep promotes the 
concept of illicit drug use for self-medication purposes rather than
hedonism. (7, 8, 9)
Presence or absence of major The similarity to alcohol regarding effects and route of administration
value conflicts may facilitate diffusion i.e. in the absence of major value conflicts 
about use. (8, 9)
Implications for social institutions In view of the pharmacological effects and known health risks there 
(school, labour, recreational, etc.) are implications for a number of social institutions: the media, drug 
and community services outreach workers, research institutes, hospital emergency departments, 
community drug and rape services, police. (4, 5, 6, 8, 9, 10)
Wholesale production and Distribution of GHB has been identified in 10 Member States, 
distribution although on a limited scale. Three Member States, France, the 
Netherlands and the UK, have information on illicit production of GHB.
Violence in connection with whole- No reliable information available.
sale production and distribution
Money-laundering aspect No reliable information available.
Involvement of (international) The Netherlands and the UK report on the role of organised crime 
organised crime in the production and trafficking of GHB. Producers are thought to
be involved also in the production of controlled drugs. They are
individuals with a criminal background or members of small groups,
rather than criminal networks.
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Topics Recorded evidence (see text for details)
The retail market GHB has marketing authority in three countries, Italy, France and
Germany, for alcohol craving, general, and other anaesthetic. Licit
and illicit retail markets provide a range of products for different
consumer groups. (1, 2, 3, 4, 5, 6, 7, 8, 9, 10)
Non-commercial ‘private’ A home-made ‘kitchen-sink’ illicit industry has developed due to 
consumption market among ease of access to precursors, information and ease of manufacture, 
users but little is known about the nature and extent of this industry and
market. (6, 8, 9, 10)
Semi-public subculture In dance settings GHB is frequently sold in liquid form in small 3 ml 
consumption market (discos, etc.) plastic bottles containing approximately 3 g of GHB, where it is
used socially for relaxation, mild euphoria or post-party for sleep.
Licit, pharmaceutical-grade GHB is also available through the
Internet, catalogue sales and specialist shops in some countries. 
The licit market has recently been curtailed by legislation and bad
publicity. (1, 6, 8, 9)
Existence and characteristic of No evidence.
street markets
Violence, public order and No evidence.
nuisance implications
Social factors that increase A range of factors such as low price, ease of availability and 
the probability of harm administration, lack of information, the need for sedation following
heavy stimulant use, and careless media coverage, increase the
probability of GHB diffusion and consequent harm. Other factors,
such as antisocial effects, relatively short duration, low status image,
mitigate against widespread diffusion and so decrease the probability
of harm. (1, 4, 8, 9, 10)
Social consequences for the user
The main social consequences of GHB for the user are linked to two different
factors: its pharmacological effects and its legal status.
Nausea, vomiting, and loss of physical control and consciousness sometimes
resulting from use of GHB may result in unpleasant or expensive conse-
quences ranging from social embarrassment to hospital admission and the
sort of invasive medical procedures, which are often used in cases of opiate
overdose, such as tracheal intubation. Home-made, ‘kitchen-sink’ GHB
products have been reported to have caused burns to mouth and lungs as a
result of large amounts of caustic soda.
Under the current laws in the European Union, the social consequences of
taking the drug or supplying friends is significantly greater in countries which
have placed GHB under drug control law, such as Denmark, France, Italy,
Table 5 (cont.)
Ireland and Sweden, than in other countries without legal controls over use.
For example legal sanctions can result in dismissal from work, criminal
records distress and stigma for the users and their families.
Consequences on the social behaviour of the user
The described loss of physical control associated with the use of GHB has
obvious consequences on the social behaviour of users and presents a high
risk for driving, cycling or operating machinery. According to outreach work-
ers in the Netherlands:
[GHB] has a very negative effect on the atmosphere … people trying
to talk and not being able to … not a nice trend, not at all.
A particular consequence that has been linked with GHB by some media
and police reports is the potential for GHB to be used surreptitiously — by
adding it to other people’s drinks — for sexual purposes, including rape
(Sturman, 2000). Such reports are difficult to substantiate because GHB is
frequently taken, knowingly, in alcoholic drinks and together with other
drugs. Also, the majority of individuals who reported sexual assault to the
police also reported that they had been in the assailant’s company and had
consumed alcohol and/or other drugs prior to the assault. GHB-assisted sex-
ual assault cases had not been drawn to the attention of the drug outreach
workers interviewed and, in the United Kingdom, GHB has been detected in
only two alleged drug rape samples submitted to the forensic science ser-
vices. In the United States, successful convictions have been based on cir-
cumstantial rather than laboratory analyses.
Other social consequences
Firstly, the ease with which GHB can be acquired, or manufactured, allows
more widespread entrepreneurial opportunity and consumer power than in
the illicit ‘ecstasy’ markets in the EU. This development can be linked to
developments in communication via the Internet. Secondly, the promotion
of GHB for health — anti-ageing and bodybuilding — through Internet sites
promotes the idea of illicit drugs being used for self-medication purposes
rather than hedonism. The representation of GHB for relaxation, sexual
enhancement and inducing sleep is strong and there appears to be a lobby
of users who wish to defend the right to use GHB for these purposes.
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However, the size of this lobby is unknown and the vested interests of GHB
producers and distributors may play a part in its visibility on the Internet.
In view of the social and health risks relating to GHB, the widespread avail-
ability of GHB and its precursors, and the ease with which it can be prepared
for consumption presents a number of implications for social institutions.
Responses by some social institutions are already evident in some Member
States.
Press and mainstream media
A recent American emergency room television series episode addressed the
issue of there being no effective intervention for treatment for an overdose of
GHB. In this episode, a doctor’s instructions regarding a patient brought in
who was known to have consumed GHB was to leave the patient in the
corridor to sleep it off.
Some types of media coverage are thought to inadvertently promote the use
of GHB. Careless coverage has been described in negative terms by drug
researchers, police and service providers. In particular, concerns have been
expressed about media coverage of GHB use in sexual assault. There is a
potential for such coverage to increase harm in the form of ‘copy-cat’ crime.
This is said to have occurred in Australia (Sturman, 2000). One example of
such coverage is in an article about GHB in the August 2000 issue of
Cosmopolitan (a women’s magazine with large international circulation fig-
ures). The article was entitled ‘The new date rape drug’ and had a subtitle
‘From health pill to rapist’s tool’. One drug worker interviewed reported that
he actively discourages journalists from covering issues such as this in main-
stream magazines and newspapers.
Research institutions
Social research on illicit use of GHB is being initiated in some countries and
questions about the use of GHB have been inserted into a music magazine
survey and a gay magazine survey in the United Kingdom, and into a mag-
azine in Australia.
Information for drug outreach workers
Drug outreach workers are a key source of information for users. Compared
with other synthetic drugs and alcohol, the sleep dose response curve of
GHB and the unpredictable effects depending on what else has been con-
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sumed have lead to the dissemination of targeted information. Both written
and verbal information highlight specific dangers about dose and about drug
and alcohol combinations to serve as a warning to users and potential users.
Information about contraindications for using GHB has also been provided.
Internet sources, which appear to be American, have advised people who
are going to use GHB to mark their hand with the letters ‘G’ or ‘GHB’ to
identify a reason for loss of consciousness, if it occurs. Admission to hospital
unconscious may lead to routine interventions for opiate overdoses, such as
intubation, and this can be very costly. By indicating that an overdose has
been caused by GHB, users have a better chance of avoiding high ambu-
lance and hospital fees.
Other advice to GHB users and ‘kitchen-sink’ producers has been to add
blue food colouring to GHB in order to help users identify it, and to prevent
both inadvertent use and/or deliberate use in drug-assisted assault.
Hospital personnel
Pharmacotoxicological information about GHB for hospital personnel may,
in some circumstances, help to prevent the adoption of unnecessary medical
procedures.
Community
In a number of urban areas, community drug and rape services have been
alerted about the use of GHB and provided with up-to-date information.
Advice to people who believe that they have been victims of drug-assisted sex-
ual assault is to provide a urine sample as early as possible (Sturman, 2000).
Workplace
Employees undergoing drug or alcohol treatment or screening may be par-
ticularly vulnerable to the use of GHB in order to avoid detection.
Police
Police doctors are usually responsible for obtaining blood and urine samples
but, in the United Kingdom, some police forces have recently advised police
constables to obtain urine samples from people reporting as victims of sex-
ual assault as soon as possible in order to increase the possibility of identi-
fying the presence of GHB (Sturman, 2000).
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Wholesale production and distribution (8)
Violence in connection with wholesale production and distribution
Member States did not provide data on violence in connection with the pro-
duction, trafficking and distribution of GHB.
Money laundering aspects
No reliable data are available on the volume of money laundering in rela-
tion to the production, trafficking and distribution of GHB.
Involvement of (international) organised crime
Contributions of Member States’ law enforcement agencies
Austria, Greece, Italy and Luxembourg have reported that until now there
have been no seizures of GHB, nor is there any information on (large-scale)
production, trafficking and distribution of GHB or on the role of organised
crime in these activities.
In Belgium, seizures of GHB are increasing considerably and in particular
during summertime, where there was an increase in seizures of small quan-
tities of GHB in liquid form and, incidentally, in capsules. In Finland, 757
millilitres of GHB were seized in seven incidents in 1998. In 1999, the
Finnish forensic laboratories analysed samples of GHB relating to total
seizures of over 3 800 grams. Also, over 5 litres of the precursor GBL were
seized. In France, a ‘kitchen-type’ laboratory was discovered in the region of
Paris and 4 kilograms of GHB were seized in August 1998. In September
1998, 503 grams of GHB were seized and in September 1999 a ‘kitchen-
type’ laboratory was discovered in Bordeaux and 80 centilitres of GHB were
seized.
In Denmark there have been five seizures of GHB since June 1999. Germany
reports 11 incidents of seizures of small, insignificant quantities of GHB. The
limited number of seizures does not allow for an assessment of the level of
production, trafficking and distribution or the role of organised crime. In
Ireland, one seizure of GHB in liquid form (25 millilitres) was reported.
In the Netherlands there were a number of small seizures in 1999, totalling
76 capsules of GHB. Producers of GHB are thought to be involved in the
production of controlled drugs, with dealers possibly having links to ecstasy
(8) Europol’s contribution to the risk assessment.
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producers. They are individuals with a criminal background or members of
small groups, rather than criminal networks. However, in January 1999, a
criminal organisation was dismantled that had been engaged for a number
of years in the production and trafficking of ‘designer drugs’, including GHB.
In Portugal, one seizure of 1 100 litres of the precursor GBL took place in
November 1999.
In Spain, 34 seizures took place in 1999, in Zaragozza (31) and Ibiza (three).
In Sweden, abuse of GHB is increasing and GHB and GBL have been found
in seizures of narcotic drugs and anabolic steroids. It is believed that GBL is
being imported into Sweden.
In the United Kingdom, London, the North-West, Midlands and South Wales
have been identified as the main areas of production and supply. There is
intelligence that the precursor, GBL, is being sourced from other Member
States, for example Belgium, to be used in GHB production. GHB is mainly
distributed through retail outlets, the Internet, via mail order and in gyms.
The disruption of overt supply has led to distribution patterns similar to illic-
it drug networks. There is no current intelligence regarding international traf-
ficking of GHB into or from the United Kingdom. The high profit margins
and the comparatively limited penalties encourage the involvement of
organised criminal groups. There is evidence of criminals involved in con-
trolled drugs also being involved in the production and supply of GHB.
Conclusions
 No Member State has information on large-scale production, trafficking
and distribution of GHB. Seizures of GHB in the European Union are very
small when compared to seizures of ‘regular’ types of synthetic drugs such
as amphetamine, MDMA and MDA.
 Three Member States — France, the Netherlands and the United Kingdom
— have information on illicit production of GHB in their country.
Production in France seems to be incidental and limited to two kitchen-
type facilities.
 Two Member States — the Netherlands and the United Kingdom — report
on the role of organised crime in the production, trafficking and distribu-
tion of GHB. In both countries producers of GHB are thought to also be
involved in the production of controlled drugs, with dealers possibly hav-
ing links to ecstasy producers. They are individuals with a criminal back-
ground or members of small groups, rather than criminal networks.
The retail market
The retail market appears to consist of both pharmaceutical grade GHB and
a wide range of home-made varieties serving a market historically predomi-
nated by homosexual men but which is making inroads into the heterosexual
population, and in particular that of recreational drug users.
GHB is authorised only in three countries: in Italy for alcoholic craving and
in France and Germany as an anaesthetic (9). In France and Italy, the com-
mercial sales figures for GHB have decreased. In France they more than halved
(from 35 547 in 1988 to 12 456 in 1999) and in Germany no sales figures are
available but it is assumed that market sales are very low (EMEA, 2000).
In some countries such as the Netherlands and the United Kingdom, GHB
has been available for a number of years through retail outlets such as smart
shops, sex shops, gyms and through mail order (Stichting Adviesburo Drugs,
1990). GHB and GHB-making kits have been widely available through
Internet sales but, in 2000, concern about the drug’s safety and changes in
marketing authorisation have led to restricted advertising and sales. GHB kits
are no longer openly sold on the Internet and in August 2000, only two
English-language Internet sites openly marketing GHB were identified. GHB
sold in this way is generally in powder form in quantities ranging from 75 g
upwards and suppliers provide strong assurances of quality (assays above
99 % , measured using gas chromatography) and discretion with regard to
packaging, encrypted transactions, and guaranteed deliveries are assured.
One laboratory appeared to be based in the United States and offered world-
wide shipping. The other, a South African-based laboratory, excluded supply
to Australia, New Zealand, Norway, South Africa or the United States.
Although Internet sales of GHB have been curtailed, a number of body-
building, anti-ageing and smart-drug web sites continue to advertise GHB
under other names such as gamma-OH, ProK, Genetika, Alcover, ReActive
and Renewtriant and Furanone Di-hydro. These GHB-type products are gen-
erally advertised as dietary supplements providing therapeutic benefits for:
inducing sleep, mood enhancement, treatment of drug and alcohol addic-
tion, sexual enhancement, athletic performance and to combat ageing. The
sites that promote the use of GHB usually provide strong cautions with
regard to doses and contraindications.
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(9) Classification for the supply of medicinal products for human use is regulated by Directive
92/26/EEC of 31 March 1992 and that Article 12 of Directive 75/319/EEC of 20 May 1975
regulated through the Committee for Proprietary Medicinal Products (CPMP) the suspen-
sions, withdrawal or variations to the terms of the marketing authorisation, in particular to
take account of the information collected in accordance with Pharmacovigilance.
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A home-made, ‘kitchen-sink’ industry developed due to the fact that GHB is
easily manufactured and no special equipment is required for this process. A
book about GHB has been published and information about recipes, taste,
effects and where to purchase precursors is exchanged via the Internet in
many different languages (Ward, 2000). In February 2000, a web site dedi-
cated to GHB alone was established.
GHB dissolves easily and is generally colourless, odourless and relatively
tasteless. Therefore, it can be taken easily and unobtrusively in social settings
where alcoholic drinks are served. In recreational drug settings, GHB is most
frequently sold in liquid form in plastic opaque bottles or screw cap doses
and in Europe, GHB synonyms in these settings include ‘GBH’ and ‘liquid
ecstasy’, ‘happiness drops’ and ‘liquid loving’. Although GHB sometimes
appears in the same market place as ecstasy it is not likely to be purchased
as, or mistaken for, ecstasy because of its distinguishing physical appearance
and its effects, which are more similar to those produced by alcohol and
other sedatives than MDMA or other stimulant drugs. The United Kingdom
focal point reported that 30 ml bottles contain about 3 g of GHB and one of
these is typically sold for approximately EUR 15. In Spain and Sweden,
prices of GHB reported by the focal points are considerably lower than in
the United Kingdom but the defining units or price sources may be different.
For example, Internet or catalogue sales prices for bulk orders are lower than
‘street level’ sales prices.
A major technical difficulty facing control of the GHB retail market is that
the precursor gamma-butyrolactone (GBL) is used industrially and is com-
mercially available at low prices and the precursor can simply be recovered
from a GHB solution by adding acid to neutralise the sodium hydroxide. In
Sweden, in 1998 approximately 40 products containing GBL in substantial
amounts were identified and 11 of them were commercially available as
consumer products. The Swedish focal point reported that a dialogue with
major importers of GBL was planned in order to trace possible leaks to clan-
destine production.
Social factors that increase the probability of harm
A major social factor that increases the probability of harm is linked to the
steep dose response curve of GHB (Elliott, 2000). Firstly, the variable and
unknown GHB content available on the illicit market makes it impossible for
individuals to assess their dose on the basis of past experience in the way
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that they do with alcohol. Secondly, there exists a small, but significant,
minority of ‘innovators’ or ‘extreme’ users who take large quantities of drugs
and alcohol as part of their social lifestyle. This group may continue to use
GHB because of its availability, low price and other factors, even if more
accurate and reliable information about dose was available to them.
With regard to the potential wider dissemination of GHB use, it appears that
GHB may have a significant role in the recreational drug scene as a self-
medication drug used to counteract some of the negative influences of stim-
ulant drugs such as sleeplessness and tension. Here the demand for GHB, or
a similar drug, is linked with the heavy or regular use of stimulants. The com-
paratively low price of GHB also provides a cheap alternative to alcohol for
young people on low incomes. The similarities of GHB to alcohol both in
terms of oral administration and effects allows easy experimentation among
mainstream youth without any major value conflict. These factors, com-
bined with perceived lack of hangover effects, could lead to widespread dis-
semination among young people. Socially excluded populations may be the
most vulnerable to widespread dissemination (EMCDDA, 2000). Mitigating
factors against widespread diffusion are the relatively low status of GHB due
to: its low price, its association with heavy alcohol use and its anti-socialis-
ing effects. The relatively short-acting effects of GHB compared with drugs
such as MDMA also mitigate against the drug gaining widespread popularity
as does the high purity and low price of MDMA that is currently evident on
the market.
Finally, another social factor that increases the probability of harm is the role
of the media in promoting harm, if inadvertently. This relates particularly to
media coverage of GHB use for the purposes of sexual assault which could
promote a small, but significant, number of ‘copy-cat’ crimes.
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Public health risks of GHB — epidemiological
evidence
Introduction
The earliest recorded indications of health risks associated with non-medical
use of GHB were in Sweden and in the United States during the early 1990s.
At that time in Sweden, the small number of GHB overdoses was associated
with bodybuilders. In the absence of systematic studies of non-medical use
of GHB, the epidemiological evidence regarding the public health risks of
GHB for this report is based on limited information collected from:
 the Reitox national focal points in the 15 EU Member States (1);
 Europol’s contribution to the risk assessment of GHB (2);
 EMEA’s contribution to the risk assessment of GHB (3);
 the Qualitative European Drugs Network (QED) (4);
 the literature (5);
 key European forensic scientists (6);
 key toxicologists in the United Kingdom (7);
 telephone interviews with international experts in the field of recreational
drugs (8);
 the Internet (English-language searches) (9); and
 youth and mass media (English-language searches) (10).
Table 6 presents the topics covered by this annex by briefly indicating the
extent and type of evidence that is available. The numbers in the list above
are used in the table to code the sources of information. Where information
is available, it is presented and examined in the text under the main catego-
ry headings. In general, there is insufficient information, or too much over-
lap, to address each of the subheadings in the text.
Following the EMCDDA request to all 15 Reitox national focal points for
information about GHB, four responded stating that they were unable to 
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Topics Recorded evidence (see text for details)
Availability and quality of product on the market
Availability at consumer level (extent/quantities) Some seizures and limited targeted survey data indi-
cate relatively low availability and use. (1, 2, 4, 6, 8)
Sources (at consumer level) Pharmaceutical laboratory and ‘kitchen-sink’ GHB
available. (6, 7, 8, 9, 10)
Trends in availability Increase in legal sanctions has reduced supply via
the Internet and illicit laboratories. (6, 9)
Average dose and degree of variability 250 mg for relaxed energy enhancement – 3 g for
profound sleep. (1, 5, 6, 9, 10)
Purity levels and presence of adulterants No evidence.
Other active ingredients No evidence.
Typical price and range Up to approximately EUR 5 per dose. (1, 6, 8)
Knowledge, perceptions and availability of 
information
Availability of scientific information on product See pharmacotoxicological review.
Availability of information on effects of product Ranges from mild energy enhancement to uncon-
sciousness. Hangover effects comparatively low. 
(4, 5, 8, 9, 10)
Level of awareness of product among drug Relatively low awareness and experimentation in 
consumers in general Europe.
Level of knowledge of product, effects and Lack of reliable knowledge about dose concentrations
perceptions among consumers of product but the Internet coverage suggests high levels of
information available among regular users. (6, 7, 8,
9, 10) 
General population No evidence but appears low. 
Prevalence and patterns of use
Extent of use of product Targeted surveys of party/dance scenes indicate
limited prevalence but it is probably higher among
some male homosexual populations. (1, 4, 8)
Frequency of use No evidence.
Route(s) of administration Usually orally in liquid form but anecdotal reports 
of limited use by inhaling. (8) 
Other drugs used in combination with product Alcohol and stimulants. (4, 8)
Geographical distribution of use Has been analysed by forensic or toxicology
laboratories in 11 Member States. (1, 2)
Trends in prevalence and patterns of use Some evidence of spread into heterosexual
recreational drug-using population. (8, 10)
Table 6: Topics for public health risks — epidemiological evidence
provide any formal evidence of GHB use in their countries (Austria, Greece,
Italy and Luxembourg). All except one of these had anecdotal reports of its use.
Laboratory analysis of samples of GHB, or its precursors, were reported by
all, except four, countries, either by focal points or by Europol. The infor-
mation provided is not always consistent in its detail and forensic analyses
of GHB samples has been, generally, very limited. The number of seizures
and quantities of GHB identified by laboratory analysis range from 3 800
grams in Finland to a single small sample of a GHB precursor identified by
the criminal police in Portugal in 2000.
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Topics Recorded evidence (see text for details)
Characteristics and behaviour of users
Age and gender of users Anecdotal evidence for it being historically more
prevalent among male homosexuals. (1, 8)
Social groups where product available/used Recreational dance scene, heavy alcohol users, 
bodybuilders. 
Risk behaviours associated with use Physical accidents and unconsciousness.
Special concerns about vulnerable groups Low income and socially excluded, drug and 
alcohol dependence. Children who may drink 
GHB inadvertently are vulnerable. (1, 3, 5)
Trends in characteristics/behaviour of users Association with anti-social behaviour, vomiting, lack
of control, sleep and unconsciousness. (8, 9, 10)
Indicators of health consequences
Hospital emergencies Five countries report non-fatal hospital admissions
associated with GHB. 
Deaths (direct and indirect) Deaths associated with GHB reported in four countries. 
Traffic accidents No evidence.
Requests for treatment/counselling No evidence.
Other health indicators Concerns expressed by drug outreach workers, club
owners, music promoters, journalists about use of
GHB in dance settings. (10)
Content of use
Risk factors linked to circumstances and rituals Steep dose response curve and anaesthetic effects 
of consumption make it very dangerous in physically active settings,
particularly for driving. Home-made ‘kitchen-sink’
varieties may carry added risks of too much caustic
soda. The close affinity to alcohol in terms of effect
and mode of consumption could make diffusion to
mainstream populations more probable. (7, 8, 9, 10)
Implications for the non-using population Increase in negative atmosphere (vomiting, slurring,
staggering and unconsciousness) in social recreational
settings. (10)
Table 6 (cont.)
There have been 11 reported deaths in which GHB was associated as cause
in the European Union between September 1995 and January 2000. The
majority of these were reported from the United Kingdom and Sweden and
most, but not all, also involved alcohol. Non-fatal hospital admissions asso-
ciated with GHB are difficult to assess in the absence of routine screening
for GHB by hospital toxicology laboratories but, as with deaths, the highest
number of reports also comes from the United Kingdom and Sweden.
Table 7 summarises key data on GHB including the indicators used.
Availability and quality of product on the market
GHB has marketing authority (10) in only three countries: in Italy for alcoholic
craving and in France and Germany as an anaesthetic (EMEA, 2000).
Growing concern about non-medical use of GHB in the United States,
Australia and Europe has prompted a number of countries to introduce new
and more stringent drug controls on GHB. Since 1998, six Member States
have put GHB under permanent control: Belgium (Decree 21.1.1998),
Denmark (Euphoriant Act, 16.12.1999), France (Decree 28.4.1999), Italy
(Decree 266, 11.11.1999), Ireland (Misuse of Drugs Act, May 1999) and
Sweden (Narcotics Act, 13.1.2000). In the United Kingdom, the
Netherlands, Austria and Finland GHB continues to be controlled by the
Medicine Act and monitoring is in progress. In the United Kingdom, the
Medicines Control Agency (MCA) has taken action against a number of unli-
censed operators. 
The effect of these changes is evident in the withdrawal of open sales of
GHB from gyms, sex shops and smart shops and in the reduced level of
advertising and open supply on the Internet of GHB and kits for making GHB
at home. More discrete methods have been adopted by suppliers of GHB
alongside the appearance of substitutes for GHB in name or content. For
example, in August 2000, one bodybuilding site was marketing Furanone
Di-hydro as a product named ‘ReActive’, claiming that it was not GHB.
Smart drug and anti-ageing sites also market products with similar effects as
GHB under a range of different names. The disruption of overt supply has
lead to distribution patterns similar to illicit drug networks.
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(10) Classification for the supply of medicinal products for human use is regulated by Directive
92/26/EEC of 31 March 1992 and that Article 12 of Directive 75/319/EEC of 20 May 1975
regulated through the Committee for Proprietary Medicinal Products (CPMP) the suspen-
sions, withdrawal or variations to the terms of the marketing authorisation, in particular to
take account of the information collected in accordance with Pharmacovigilance.
Availability at consumer level (extent/quantities)
In addition to GHB being made available via the Internet and other discrete
retail outlets, a home-made ‘kitchen-sink’ GHB industry has developed due
to the fact that it is easily manufactured (Elliott, 2000) and no special equip-
ment is required for this process.
Seizures
Austria, Greece, Italy and Luxembourg have reported that until now there
have been no seizures of GHB. In Belgium, there are regular seizures, par-
ticularly during the summertime, when there is an increase in seizures of
small quantities of GHB in liquid form and capsules. GBL is more common-
ly found than GHB and seizures usually occur near the Dutch border. In
1999, Spain reported 31 seizures in Zaragozza and three in Ibiza. In
Sweden, police seizures have found GHB in connection with other seizures
of narcotic drugs and anabolic steroids. In Denmark, since June 1999, there
have been five seizures of GHB providing six samples. In 1999, the Finnish
forensic laboratories analysed samples of GHB relating to total seizures of
over 3 800 grams. Germany reported 11 seizures of small insignificant quan-
tities of GHB. In 1999 in the Netherlands there were a number of small
seizures totalling 76 capsules of GHB. In the United Kingdom the forensic
science service handles less than 10 cases each year. In Ireland two seizures
were made, one of GHB in liquid form and one in powder. In France there
have been few seizures reported (Europol, 2000).
Dose and price
In recreational drug settings, GHB is most frequently sold in liquid form in
plastic opaque bottles or screw-cap doses and samples found to contain
GHB, which have been analysed by the DIMS project in the Netherlands are
commonly submitted already mixed with alcohol. Police sources in Europe
have made seizures in liquid, powder and capsule form.
Advised doses range from 250 to 500 mg for energy enhancement, 500 to
1 000 mg for euphoria/libido enhancing effects, and up to 3 grams for pro-
found relaxation and sleep. The United Kingdom focal point reports that
standard 30 ml bottles contain about 3 g of GHB but the amount of GHB
contained in the bottles consumed in recreational dance settings and else-
where across Europe is likely to vary considerably. There have been some
reports of burns to mouths due to high caustic soda content in home-made
varieties.
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The liquid form is generally taken in capfuls by cautious users or ‘swigged’
from the bottle, less cautiously by others. In the United Kingdom, one of
these bottles is typically sold for approximately EUR 15. In Spain and
Sweden, prices of GHB reported by the focal points are considerably lower
but this is likely to be the result of different unit definitions and different
sources. For example, the number of doses in a 3 ml bottle varies and prices
for Internet or catalogue bulk order sales are lower than the 30 ml bottle
price at ‘street level’.
Knowledge, perceptions and availability of information
Knowledge and availability of information
The scientific knowledge about GHB is summarised in the review of phar-
macotoxicological data on GHB (Elliott, 2000).
The knowledge and perceptions of GHB among the general EU population
are not known, but are probably limited and subject to a low level of media
reporting. The most significant lack of information about GHB is with regard
to the variable strengths and quantities of GHB contained in ‘street sales’ and
the lack of predictable effects for individuals.
For the populations who use recreational drugs, smart drugs or bodybuilding
drugs information about GHB is mostly made available through the social
networks which serve those populations. A vast number of Internet sites and
newsgroups (4 300 in the English language identified from one search
engine) feed into these networks and promote the use of GHB for a wide
range of purposes including inducing sleep, mood enhancement, treatment
of drug and alcohol addiction, sexual enhancement, athletic performance
and combating ageing. One anti-ageing site reproduced a graph of a
Japanese clinical study that showed that a dose of 2.5 grams of GHB dra-
matically increased growth hormone levels 16 times within 60 minutes.
Information about recipes, taste, effects and where to purchase supplies and
alternatives to GHB is available in many different languages and many offer
warnings with regard to doses and highlight the contraindications for use. In
February 2000, a web site dedicated to GHB was established (www.ghb.org)
and a book specifically about GHB has been published and distributed
through major bookstores in the United States and via the Internet (Ward,
2000).
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Perceptions
There appears to be a lobby of GHB users and promoters, visible in Internet
discussion groups, which has recently put forward a conspiratorial view of
the American government and pharmaceutical industry’s strategies regarding
trials with GHB. Whilst government sanctions against the use of GHB are
increased, the GHB trials may result in FDA approval for GHB to be autho-
rised as a prescription drug for treating sleep disorders.
Within recreational drug settings, anecdotal reports suggest that the negative
effects of GHB with regard to associated nausea, unpredictable doses, sub-
sequent risks of losing physical control or consciousness and its generally
negative low-status image will restrict its popularity in widespread social set-
tings. Unlike MDMA, it appears to be considered an antisocial drug among
mainstream trend setters, music promoters, club owners and outreach work-
ers. For example, an outreach worker in Amsterdam described it as having:
a very negative effect on the atmosphere — we don’t like it
In the United Kingdom, club promoters and youth magazines are beginning
to speak out about the use of GHB. The April 2000 issue of Mixmag gave
four full pages to the coverage of information about GHB with the subhead-
ing: ‘Some call it the nastiest drug in Britain, others offer prayers at its alter.
What’s the truth about GHB? And what’s it doing to you’.
Prevalence and patterns of use
There are no data specifically on prevalence or on patterns of the use of
GHB and at present there is little evidence that GHB is used on a wide scale
in any EU Member State. However, there is evidence of its use predomi-
nantly in the male homosexual social scene in the past and of it now mak-
ing inroads into heterosexual sub-populations for recreational purposes, into
the wider ecstasy market and into post-party settings (Newcombe, 1999).
According to the risk assessment conducted in the Netherlands, GHB is most
commonly found in Germany, the Netherlands and the United Kingdom
(CAM, 1999).
In the Netherlands, some use of GHB in party settings has been reported by
drug workers.
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In parts of the United Kingdom, use of GHB is reported as having an affinity
with heavy alcohol users. However, a Liverpool study of 100 United
Kingdom clubbers over the Christmas period 1999–2000 found that nobody
had used GHB. A survey in France conducted in 1998 found that 3 % of reg-
ular techno party goers said they had taken GHB but among a matched con-
trol group consumption of GHB was non-existent, indicating that the use of
GHB is also not widespread in France (Médecins du Monde, 1999). The
French survey indicated that GHB was not only taken for the effects it
induced but that, in association with other substances, it enhanced the over-
all effects or facilitated the ‘come down’ from taking stimulant drugs. The
Swedish report also indicates that GHB is not the drug of choice but used as
a complement to other drugs. A survey in Helsinki conducted in May 2000
suggested that the popularity of GHB had decreased since 1998 because of
supply restrictions and relatively short effects compared with MDMA
(www.qed.org).
Social research on illicit drug use is generally limited to recreational dance
or treatment settings, yet anecdotal and Internet evidence suggests that use
of GHB may not be confined to recreational party drug settings. Some spe-
cific sub-populations appear to use GHB for specific effects — for example,
both gay and heterosexual men for its perceived muscle building and sexu-
al enhancement properties, stressed professionals to induce sleep, and mid-
dle-aged populations for anti-ageing and sexual benefits. The Austrian focal
point reinforced this view with some anecdotal evidence of use among very
small closed groups outside the dance drug setting. Internet postings and
outreach workers suggest that GHB can also be used as a substitute for alco-
hol or drugs to achieve inebriation whilst avoiding detection tests in treat-
ment, the workplace and for driving. Some police sources and media cover-
age have expressed concern about the ease with which GHB may be used
to facilitate sexual assault.  In this regard, Internet newsgroups discussions,
not infrequently, counter suggestions that GHB is tasteless by addressing the
issue of the bitter or unpleasant taste experienced by users.
It is clear that there is a considerable amount of information about GHB on
the Internet, in magazines, and media. However, the significance of this
information for the task of estimating the prevalence of its use is difficult to
interpret for a number of reasons. Also the role that media reports play in
reflecting or promoting harmful drug trends is not well understood.
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Characteristics and behaviour of users
The limited information that is available about the characteristics and behav-
iour of users has been reported above. However, it should be noted that the
comparatively low price of GHB provides a cheap alternative to alcohol and
when used for illicit purposes the effects of GHB are much closer to those
produced by alcohol, marijuana and diazepam than they are to MDMA and
other stimulant drugs. One drug worker in the United Kingdom observed
that the use of GHB was more prevalent among heavy alcohol users and
another in the Netherlands commented that he did not understand why
young people wanted to use GHB for going out. Compared with alcohol, the
physical incapacity and unconsciousness resulting from a relatively small
increase in GHB doses demonstrates that health risks in relation to road traffic
or operating machinery are particularly high.
Indicators of health consequences
Deaths
There have been 11 deaths in which GHB was implicated in the European
Union. In the United Kingdom between September 1995 and January 1999,
four deaths occurred in the United Kingdom associated with GHB in com-
bination with alcohol. In Sweden, the official number of fatal GHB intoxi-
cations is four and in a fifth death GHB was identified but not considered to
be the cause of death. In Finland, two deaths have been reported and in
January 2000 one death was reported in Denmark (concentration of 34 mg
GHB/kg and alcohol blood content of 0.27). The majority of deaths also
involved alcohol.
Non-fatal hospital admissions
Non-fatal hospital admissions are difficult to assess in the absence of routine
screening for GHB by hospital toxicology laboratories (Hernandez M. et al.,
1998). From April 1996 to mid-1999, over 150 non-fatal intoxications were
reported in the United Kingdom. In 1997, following six hospital admissions
involving GHB in the Netherlands a study was conducted. The study
analysed blood and urine samples from 50 patients with suspected ecstasy
intoxication and consumption of GHB was confirmed in three patients out
of the 50.
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More recently, since mid-1999, the United Kingdom reports that approxi-
mately 60 non-fatal intoxications involving GHB are treated in hospital each
year, whereas in the Netherlands none have been reported. In Denmark
there have been 12 reported non-fatal intoxications involving GHB since
mid-1999: in three of these cases the patients were unconscious on arrival
and in three cases GHB had been consumed in combination with alcohol.
In Sweden over 20 non-fatal hospital admissions were reported. The most
recent reports have come from Belgium where two non-fatal intoxications
were reported in July 2000. The French have not provided figures for GHB
intoxications or deaths associated with illicit use but the Pharmacovigilance
report submitted by the EMEA highlights the existence of overdose reports,
dependence and accidental poisoning of children (EMEA, 2000).
In 1998, the Advisory Council on the Misuse of Drugs considered whether
GHB should be controlled and concluded that it did not present a sufficient
social problem and in 1999 a risk assessment of GHB conducted in the
Netherlands also recommended continued monitoring (CAM, 1999).
Context of use
An important factor with regard to context of use is the lack of reliable indi-
cations of dose accompanying sales of GHB at ‘street level’. However, the
steep dose response curve of GHB makes it risky for recreational use even
where dose is both accurately measured and known (Elliott, 2000). The com-
bination of GHB with other drugs, particularly alcohol and other sedative
drugs also increases substantially the risks related to taking GHB as does tak-
ing GHB when suffering medical conditions such as epilepsy, hypertension
and diabetes. GHB taken at home for relaxation or sleep without combining
it with other drugs or alcohol reduces the risks of physical accidents and the
social/psychological harm associated with the drug. The continued and
heavy use of stimulant drugs which creates the need for the type of sedative
effects offered by GHB is likely to increase the demand for GHB. Also the
close affinity of GHB to alcohol, in terms of effect and mode of consump-
tion, could make diffusion to mainstream populations more probable, par-
ticularly to those with low incomes and with drug or alcohol problems.
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Implications for the non-using population
At present, the main implications for the non-using population appear to be
the increasingly negative atmosphere (vomiting, slurring, staggering and
unconsciousness) described in social recreational settings.
In the absence of traffic controls to prevent GHB users from driving there is
a risk for road users.
Table 7: Summary of key data on GHB
Date Place Comment
Illicit use first Early 1990s Sweden 4–5 cases per annum of non-fatal overdose among 
identified bodybuilders
United States 57 overdoses in 5 months
1991 United Kingdom First came to attention
April 1994 Spain Came to attention in a study of synthetic drugs
1995 Belgium Sold in smart shops 
Netherlands Six overdoses in Rotterdam
Marketing Current Italy Authorised for alcohol craving
authority France Authorised for surgery and alcohol treatment
Germany Authorised for general anaesthesia
Legal controls 1996 Netherlands Controlled under Medicines Act — now being monitored
1998 United Kingdom Controlled under Medicines Act. ACMD recommended
monitoring but not control
Austria Controlled under Medicines Act
Finland Controlled under Medicines Act
Jan. 1998 Belgium Control under Royal Decree
May 1999 Ireland Decision to control under Misuse of Drugs Act
Nov. 1999 Italy Control under drug law and GBL scheduled
Dec. 1999 France Control under Narcotic Act entered into force
Dec. 1999 Denmark Control under Euphorians Act
Feb. 2000 Sweden Control under Narcotics Act entered into force
Large seizures Aug. 1998 France 4 kilograms of GHB
1999 Finland 3 800 grams and over 5 litres of GBL
Nov. 1999 Portugal 1 100 litres of GBL
Small seizures  1996–99 Spain 34 seizures — mainly in Zaragozza
/chemical 1998 Finland Seven incidences amounting to 757 millilitres
analyses 1999 Netherlands Small seizures from geographically-spread discotheques
Aug. 1998 France One small ‘kitchen-sink’ laboratory
May + Sept. Two single sample seizures in different regions and one
1999 small ‘kitchen-sink’ laboratory
July 1999 Denmark Five seizures
To date Germany 11 incidents of small seizures
To date Sweden GHB found in association with narcotics and steroid drugs
To date Belgium Regular seizures especially in the north near the 
Netherlands 
To date Ireland Two individual samples
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Date Place Comment
Laboratory To date Netherlands Illicit production identified
investigations United Kingdom 10 reports of illicit/attempted manufacture by 
unlicensed operators
Deaths 1996–99 Sweden Four deaths in different cities
associated 1995–99 United Kingdom Four deaths
with GHB 1998–99 Finland Two deaths (one remains open)
Jan. 1999 Denmark One death
Non-fatal 1996–97 Netherlands Nine patients admitted to hospital — six in Rotterdam
intoxications 1996–97 United Kingdom Approximately 150 people treated
June 1999 Denmark 12 patients treated in hospital
1999 Sweden 20 cases in nine months
July 2000 Belgium Two cases
Italy Two cases
France Child/children admitted with accidental poisoning
(EMEA Pharmacovigilance) 
Source notes — There are few data on seizures because in most EU Member States it is not,
or has not been, a controlled drug. Records of hospital admissions are subject to variations
in practice, nevertheless the recorded incidence of intoxications associated with GHB is
notably higher than those associated with ketamine and MDMA with higher prevalence use.
Pattern and effects — GHB is unlikely to be mistakenly consumed as ecstasy. Effects are
much closer to alcohol than to MDMA and, unlike MDMA, it is usually taken orally in
liquid form, often in alcohol. 
Health risks — The main concern is the steep dose-response curve. When combined with
alcohol, or other sedative drugs, risks are increased.
Diffusion — Reports suggest GHB is not widely used in Europe. Highest use appears to be
in the United Kingdom, Sweden, Germany and the Netherlands. Among small groups it
may be used for recreational nightlife, bodybuilding, inducing sleep, an alcohol/drug
substitute, sexual relaxation and disinhibition.  
Table 7 (cont.)
References
Addolorato G., et al. (1999) ‘GHB in the treatment of alcohol withdrawal
syndrome: a randomised comparative study versus a benzodiazepine’,
Alcoholism: Clinical and Experimental Research, 23 (No 10), pp.
1596–1604.
Anderson, D. T. and Kuwahara, T. (1997) ‘Endogenous GHB levels in post
mortem specimens’, Proc. California Association of Toxicologists, United
States.
Anderson, R. A., Ritzmann, R. F. and Tabakoff, B. (1977) ‘Formation of GHB
in brain’, Journal of Neurochemistry, 28, pp. 633–9.
Appleton, P. J. and Burn, J. M. B. (1968) ‘A neuroinhibitory substance: GHB,
preliminary report of first clinical trial in Britain’, Anesthesia Analgesia
Current Research, 47, pp. 164–70.
Australian Drug Foundation (ADF), http://www.adf.org.au.
Badcock, N. R. and Zotti, R. (1999) ‘Rapid screening test for GHB in urine’,
Therapeutic Drug Monitoring, 21, p. 376.
Baselt, R. C. (2000) ‘GHB’ in Disposition of Toxic Drugs and Chemicals in
Man, 5th Edition, Chemical Toxicology Institute, California, pp. 386–8.
Benavides, J., Rumigny, J. F. et al. (1982) ‘High affinity binding site for GHB
in rat brain’, Life Sciences, 30, pp. 953–61.
Benavides, J. et al. (1982) ‘A high affinity, Na+ dependent uptake system for
GHB in membrane vesicles prepared from rat brain’, Journal of
Neurochemistry, 38, pp. 1570–5.
Bessman, S. P. and Fishbein, W. N. (1963) ‘Gamma-hydroxybutyrate, a nor-
mal brain metabolite’, Nature, 200 (No 4912), pp. 1207–8.
Bowey, N. G. (1989) ‘GABAB receptors and their significance in mammalian
pharmacology’, Trends in Pharmacological Sciences, 10, pp. 401–7.
Broughton, R., and Mamelak, M. (1979) ‘The treatment of narcolepsy-cata-
plexy with nocturnal GHB’, Canadian Journal of Neurological Sciences, 6,
pp. 1–6.
77
Bustos, G. and Roth, R. H. (1972) ‘Effect of GHB on the release of
monoamines from the rat striatum’, British Journal of Pharmacology, 44,
pp. 817–820.
Cabrera, R., Torrecilla, J. M., et al. (1998) ’Gammahidroxibutirato (GHB)’,
Manual de Drogodependencias, pp. 151–3.
CAM, (1999) ‘Evaluation des risques relatifs au Gammahydroxybutyrate
(GHB)’, Coordinatiepunt Assessment en Monitoring Nieuwe Drugs (CAM),
The Hague, Netherlands.
Cash, C. D. (1994) ‘GHB: an overview of the pros and cons for it being a
neurotransmitter and/or a useful therapeutic agent’, Neuroscience and
Biobehavioral Reviews, 18 (No 2), pp. 291–304.
Center for Disease Control (CDC) (1999) ‘Adverse events associated with
ingestion of GBL — Minnesota, New Mexico and Texas 1998–1999’,
Morbidity and Mortality Weekly Report, 48 (No 7), pp. 137–40.
Center for Disease Control (CDC) (1997) ‘GHB use’, Morbidity and Mortality
Weekly Report, 46, pp. 281–3.
Center for Disease Control (CDC) (1990) ‘Epidemiologic notes and reports
multistate outbreak of poisoning associated with illicit use of GHB’,
Morbidity and Mortality Weekly Report, 39, (No 47), pp. 861–3.
Center for Disease Control (CDC) (1997) ‘GHB use — New York and Texas
1995–1996’, Morbidity and Mortality Weekly Report, Vol. 46 (No 13):
281–3.
Cheramy, A., Nieoullon, A. and Glowinski, J. (1977) ‘Stimulating effects of
GHB on dopamine release from the caudate nucleus and the substantia nigra
of the cat’, Journal of Pharmacology and Experimental Therapeutics, 203,
pp. 283–93.
Chin, M-Y., Kreutzer, R. A. and Dyer, J. E. (1992) ‘Acute poisoning from GHB
in California’, Western Journal of Medicine, 156, pp. 380–4.
Chin, R. L. et al. (1998) ‘Clinical course of GHB overdose’, Annals of
Emergency Medicine, 31 (No 6), pp. 716–22.
Colombo, G. et al. (1995) ‘Oral self-administration of GHB in the rat’,
European Journal of Pharmacology, 285 pp. 103–7.
Couper, F. J. and Logan, B. K. (2000) ‘Determination of GHB in biological
specimens by GC-MS’, Journal of Analytical Toxicology, 24, pp. 1–7.
78
Davis, L. G. (1999) ‘Fatalities attributed to GHB and related compounds’,
Southern Medical Journal, 92 (No 10), p. 1037.
De Feudis, F. and Collier, B. (1976) ‘Amino acids of brain and GHB-induced
depression’, Archives of International Pharmacodynamics and Therapeutics,
187, pp. 30–6.
Delay, J. et al. (1993) ‘GHB and narcolepsy: a double blind placebo-con-
trolled study’, Sleep, 16, pp. 216–20.
Diedrich, U. et al. (1996) ‘GHB in the treatment of increased intracranial
pressure and vasospasm’, Aktuelle Neurologie, 23 (No 2), pp. 63–67.
Dyer, J. E., Kreutzner, R. et al. (1991) ‘Multistate outbreak of poisoning asso-
ciated with illicit use of GHB’, Journal of American Medical Association,
265, pp. 447–8.
Dyer, J. E. (1991) ‘GHB: a health food product producing coma and seizure-
like activity’, American Journal of Emergency Medicine, 9 (No 4), pp. 321–4.
Dyer, J. E., Isaacs, S. M. and Keller, K. H. (1994) ‘GHB-induced coma with
serum and urine drug levels’, Veterinary and Human Toxicology, 36, p. 348.
Dyer, J. E., Galbo, M. J. and Andrews, K. M. (1997) ‘1,4-butanediol, ‘pine
needle oil’; overdose mimics toxic profile of GHB’, Journal of Clinical
Toxicology, 35, p. 554.
Eckstein, M. et al. (1999) ‘GHB: report of mass intoxication and review of
literature’, Prehospital Emergency Care, 3 (No 4), pp. 357–61.
El Sohley, M. A. and Salamone, S. J. (1999) ‘Prevalance of drugs used in
cases of alleged sexual assault’, J. Anal. Toxicology, 23 (No 3), pp. 141–6.
Elliott, S. P. (2000) ‘Analysis of GHB in biological fluid using gas chro-
matography’, Meeting of Association Clinical Biochemists (ACB),
Birmingham, United Kingdom, 2000.
Elliott, S. P. (2000) Review of the Pharmacotoxicological Data on Gamma-
Hydroxybutyric Acid (GHB), City Hospital NHS Trust, Birmingham, United
Kingdom, Report commissioned by the EMCDDA for the risk assessment on
GHB in the framework of the joint action on new synthetic drugs.
EMEA (2000) Contribution to the Risk Assessment (EMEA/H/9199/01),
London, United Kingdom.
79
Entholzner, E. et al. (1995) ‘EEG changes during sedation with GHB’,
Anaesthetist, 44 (No 5), pp. 345–50.
EROWID, http://www.erowid.org.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA),
Lisbon, Portugal. Personal Communication.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
(2000) Scientific Monograph 4, Understanding and Responding to Drug Use:
The role of qualitative research, Lisbon, Portugal.
Europol (2000) Contribution to the risk assessment (2564-107), The Hague,
Netherlands.
Fadda, F. et al. (1989) ‘Suppression by GHB of ethanol withdrawal in rats’,
Alcohol and Alcoholism, 24, pp. 447–51.
Feigenbaum, J. J. and Howard, S. G. (1996) ‘Does GHB inhibit or stimulate
central DA release?’, International Journal of Neurosciences, 88 (No 1-2),
pp. 53–69.
Ferrara, S. D. et al. (1993) ‘Therapeutic GHB monitoring on plasma and
urine by GC-MS’, Journal of Pharmaceutical and Biomedical Analysis, 11
(No 6), pp. 483–7.
Ferrara, S. D., Tedeschi, L., Frison, G. and Rossi, A. (1995) ‘Fatality due to
GHB and heroin intoxication’, Journal of Forensic Sciences, 40 (No 3),
pp. 501–4.
Ferrara, S. D. et al. (1999) ‘Effects of single dose of GHB and lorazepam on
psychomotor performance and subjective feelings in healthy volunteers’,
European Journal of Clinical Pharmacology, 54 (No 11), pp. 821–7.
Fieler, E. L., Coleman, D. E. and Baselt, R. C. (1998) ‘GHB concentrations in
pre and post mortem blood and urine’, Clinical Chemistry, 44, p. 692.
Food and Drug Administration (FDA) (1990) ‘GHB warning’, FDA News, 8
(No 11), pp. 1–2.
Food and Drug Administration (FDA) (1997) ‘Updates: injuries, deaths linked
again to GHB abuse’, FDA Consumer, 31, p. 2.
Gallimberti, L. et al. (1989) ‘GHB for treatment of alcohol withdrawal syn-
drome’, Lancet II, pp. 787–9.
80
Gallimberti, L. et al. (1992) ‘GHB in the treatment of alcohol dependence: a
double blind study’, Alcoholism: Clinical and Experimental Research, 16
(No 4), pp. 673–76.
Gallimberti, L. et al. (1993) ‘GHB for treatment of opiate withdrawal syn-
drome’, Neuropsychopharmacology, 9 (No 1), pp. 77–81.
Galloway G. P. et al. (1997) ‘Gamma-hydroxybutyrate (GHB): an emerging
drug of abuse that causes physical dependence’, Addiction, 92 (No 1),
pp. 89–96.
Giarman, N. J. and Schmidt, K. F. (1963) ‘Some neurochemical aspects of the
depressant action of gamma-butyrolactone (GBL) on the central nervous sys-
tem’, British Journal of Pharmacology, 20, pp. 563–8.
Gessa, G. L. et al. (1966) ‘Selective increase of brain dopamine induced by
GHB’, Life Sciences, 5, pp. 1921–30.
Godbout, R. et al. (1991) ‘Inhibitory influence of the mesocortical dopamin-
ergic neurons on their target cells: electrophysiological and pharmacological
characteristics’, Journal of Pharmacology and Experimental Therapeutics,
258, pp. 728–38.
Godbout, R. et al. (1995) ‘Effect of GHB and its antagonist NCS-382 on
spontaneous cell firing in the firing in the prefrontal cortex of the rat’, Brain
Research, 673, pp. 157–60.
Hale, K. A., Regional Laboratory for Toxicology, Birmingham, United
Kingdom. Personal Communication.
Hechler, V., Gobaille, S. et al. (1991) ‘Extracellular events induced by GHB
in striatum in micro-dialysis study’, Journal of Neurochemistry, 56,
pp. 938–44.
Helrich, M., McAslan, T. C., Skolnick, S. and Bessman, S. P. (1964)
‘Correlation of blood levels of GHB with state of consciousness’,
Anesthesiology, 25, pp. 771–5.
Hernandez, M. et al. (1998) ‘GHB-induced Delirium: A Case report and
Review of the Literature on Gamma Hydroxybutyric Acid’, American Journal
of Drug and Alcohol Abuse, 24 (10), pp. 179–83.
Hoes, M., Vree, T. B. and Guelen P. J. M. (1980) ‘GHB as a hypnotic’,
L’Encephale, 6, pp. 93–9.
81
Hovda, K. E., Liberg, J. P., Nordby, G. and Jacobsen, D. (1998) ‘GHB — an
endogenous substance and an intoxicant’, Tidskkr. Nor. Laegeforen., 118
(No 28), pp. 4390–3.
Hunderup, M. C. and Jorgensen, A. J. (1999) ‘Poisoning with gamma-hydrox-
ybutyric acid’, Cases reported in connection with ‘cultural festivals’ in
August 1999 in Kolding, Ugesker Laeger, 161 (No 50), pp. 6939–40.
Kam, P. C. A. and Yoong, F. F. Y. (1998) ‘Gamma-hydroxybutyric acid: an
emerging recreational drug’, Anaesthesia, 53, pp. 1195–8.
Kato, Y., Nakai, Y., Imura, H., Chinara, K. and Ohgo, S. (1974) ‘Effect of 5-
hydroxytryptophan (5-HTP) on plasma prolactin levels in man’, Journal of
Clinical Endocrinology & Metabolism, 38, p. 695.
Kaufman, E. E., Nelson, T., Goochee, C. and Sokoloff, L. (1979) ‘The purifi-
cation and characterisation of a NADP+-linked alcohol oxido-reductase
which catalyses the interconversion of GHB and succinic semialdehyde’,
Journal of Neurochemistry, 32, pp. 699–712.
Kleinschmidt, S. et al. (1995) ‘GHB — Hat sie einen Stellenwert in
Anästhesie und Intensivmedizin?’, Anästhesiol. Intensivemed.
Schmerztherapie, 30, pp. 393–402.
Knudsen, K. (2000) ‘Intoxication with GHB is an increasing social and med-
ical emergency in Sweden’, 20th International Congress of the European
Association of Poison Centres and Clinical Toxicologists (EAPCCT),
Amsterdam, Netherlands.
Laborit, H. (1964) ‘Sodium 4-hydroxybutyrate’, International Journal of
Neuropharmacology, 3, pp. 433–49.
Laborit, H. (1972) ‘Correlations between protein and serotonin synthesis dur-
ing various activities of the central nervous system (slow and desynchronised)
sleep, learning and memory, sexual activity, morphine tolerance, aggressive-
ness and pharmacological action of sodium gamma-hydroxybutyrate’,
Research Communications in Chemical Pathology and Pharmacology, 3,
pp. 51–81.
Le Gatt, D. F., Singer, P. P. and Jones, G. R. (1999) ‘GHB on the Internet’,
Clinical Chemistry Supplement A130, 464a.
Lenzenhuber, E. et al. (1999) ‘GHB for therapy of alcohol withdrawal syn-
drome in intensive care patients: a comparison between two symptom-trig-
gered therapeutic regimens’, Anaesthesist, 48 (No 2), pp. 89–96.
82
83
Lettieri, J. and Fung, H. L. (1978) ‘Improved pharmacological activity via
pro-drug modification: comparative pharmacokinetics of sodium gamma-
hydroxybutyrate and GBL’, Research Communications in Chemical
Pathology and Pharmacology, 22, pp. 107–118.
Levy, M. I. et al. (1983) ‘Gamma-hydroxybutyrate in the treatment of schiz-
ophrenia’, Psychiatry Research, 9 (No 1), pp. 1–8.
Li, J., Stokes, S. A. and Woekener, A. (1998) ‘A tale of novel intoxication: seven
cases of GHB overdose’, Annals of Emergency Medicine, 31 (No 6), pp. 723–8.
Li, J., Stokes, S. A. and Woekener, A. (1998) ‘A tale of novel intoxication: a
review of the effects of GHB with recommendations for management’,
Annals of Emergency Medicine, 31 (No 6), pp. 729–36, 1998.
London Toxicology Group, http://www.londontox.org.
Louagie, H. K. et al. (1997) ‘A sudden awakening from a near coma after
combined intake of GHB and ethanol’, Journal of Clinical Toxicology, 35
(No 6), pp. 591–4.
The Lycaeum, http://www.lycaeum.org.
McCusker, R. R. et al. (1999) ‘Analysis of GHB in urine by gas chromatogra-
phy-mass spectrometry (GC-MS)’, J. Anal. Toxicology, 23, pp. 301–5.
Maitre, M. et al. (1990) ‘A specific GHB receptor ligand possess both antag-
onistic and anticonvulsant properties’, Journal of Pharmacology and
Experimental Therapeutics, 255, pp. 657–63.
Mamelak, M., Escruin, J. M. and Stokan, O. (1977) ‘The effects of GHB on
sleep’, Biological Psychiatry, 12 (No 2), pp. 273–88.
Mamelak, M., Scharf, M. B. and Woods, M. (1986) ‘Treatment of narcolepsy
with GHB — a review of clinical and sleep laboratory findings’, Sleep, 9
(No 1), pp. 285–9.
Mamelak, M. (1989) ‘Gamma-hydroxybutyrate: an endogenous regulator of
energy metabolism’, Neuroscience and Biobehavioral Reviews, 13,
pp. 187–98.
Mandel, P., Maitre, M., Vayer, P. et al. (1987) ‘Function of GHB: a putative
neurotransmitter’, Biochemistry Society Transactions, 15, pp. 215–7.
Marcus, R., Winter, W., Mori, K. and Spooner, C. (1967) ‘EEG and behav-
ioural comparison of the effects of GHB, GBL and short chain fatty acids in
the rat’, International Journal of Neuropharmacology, 6, pp. 175–85.
84
Mathivet, P. et al. (1997) ‘Binding characteristics of GHB as a weak but
selective GABAB receptor agonist’, European Journal of Pharmacology, 321,
pp. 67–75.
Maxwell, R. and Roth, R. H. (1971)‚ ‘Conversion of 1,4-butanediol to GHB
in rat brain and in peripheral tissue’, Biochemical Pharmacology, 21,
p. 1521.
Médecins du Monde, (1999) Rapport de Recherche-Action: Usages de
Drogues de Synthese (Ecstasy, LSD, Dance-pills, Amphetamines …) Paris,
France.
Metcalf, D. R., Emde, R. N. and Stripe, J. T. (1966) ‘An EEG-behavioural
study of sodium hydroxybutyrate in humans’, Electroencephalography and
Clinical Neurophysiology, 20, pp. 506–12.
Microgram (1999) Gamma Hydroxybutyric Acid (GHB) analysed by
Louisiana State Police Crime Laboratory, DEA, Washington.
Mixmag (2000) ‘Drug taking is reaching epidemic proportions’, Issue 110,
Vol. 2, p. 23.
Nelson, T. and Kaufman, E. E. (1994) ‘Developmental time course in the
brain and kidney of two enzymes that oxidise GHB’, Developmental
Neuroscience, 16, pp. 352–8.
Newcombe, R. (1999) ‘Cocaine and GHB: Overview of two new trends in
dance drugs’, Paper presented to the Release Conference June 1999, 3D
Research, Liverpool.
Nissbrandt, H. and Engberg, G. (1996) ‘The GABAB-receptor antagonist,
CGP 35348, antagonises GHB and baclofen-induced alterations in locomo-
tor activity and forebrain dopamine levels in mice’, Journal of Neural
Transmission, 103, pp. 1255–63.
Palatini, P., Tedeschi, L. et al. (1993) ‘Dose-dependent absorption and elim-
ination of GHB in healthy volunteers’, European Journal of Clinical
Pharmacology, 45, pp. 353–6.
Personne, M. and Landgren, A. (2000) ‘GHB intoxication in Sweden’, 20th
International Congress of the European Association of Poison Centres and
Clinical Toxicologists (EAPCCT), Amsterdam, Netherlands.
Pichlmeier, R. and Schneck, H. J. (1991) ‘GHB for basic sedation in inten-
sive care medicine, Intensiv-und Notfallbehandlung’, 16 (No 3), pp. 106–12.
Poldrugo, F. and Snead, O. C. (1984) ‘1,4-butanediol, GHB and ethanol:
relationships and interactions’, Neuropharmacology, 23 (No 1), pp. 109–13.
Pospiech, R. and Schmidt, E. (1993) ‘Use of GHB in patients on long-term res-
piratory therapy’, Intensiv-und Notfallbehandlung, 18 (No 4), pp. 157–64.
Rambourg-Schepens, M. O., Buffet, M., Durak, C. and Mathieu-Nolf, M.
(1997) ‘GBL poisoning and its similarities to GHB: two case reports’,
Veterinary and Human Toxicology, 39, pp. 234–5.
Ratomponirina, C., Hode, Y., Hechler, V. and Maitre, M. (1995) ‘GHB recep-
tor binding in rat brain is inhibited by guanyl nucleotides and pertussis
toxin’, Neuroscience Letters, 189, pp. 51–3.
Roth, R. H. and Giarman, N. J. (1966) ‘GBL and GHB — distribution and
metabolism’, Biochemical Pharmacology, 15, pp. 1333–48.
Roth, R. H. and Giarman, N. J. (1968), ‘Evidence that central nervous system
depression by 1,4-butanediol is mediated through a metabolite, GHB’,
Biochemical Pharmacology, 17, p. 735.
Roth, R. H. and Giarman, N. J. (1969) ‘Conversion in vivo of GABA to GHB
in mammalian brain’, Biochemical Pharmacology, 18, pp. 247–50.
Scarf, M. et al. (1985) ‘The effects and effectiveness of GHB in patients with
narcolepsy’, Journal of Clinical Psychiatry, 46, pp. 222–5.
Schultz, S. C. et al. (1981) ‘Gamma-hydroxybutyrate treatment of schizo-
phrenia: a pilot study’, Pharmacopsychiatria, 14 (No 4), pp. 129–34.
Scotti de Carolis, A. and Massotti, M. (1978) ‘EEG and behavioural investi-
gations on ‘gabaergic’ drugs; muscimol, baclofen and sodium hydroxybu-
tyrate — implications on human epileptic studies’, Progress in Neuro-psy-
chopharmacology & Biological Psychiatry, 2, pp. 431–2.
Scrima, L. et al. (1990) ‘The effects of GHB on the sleep of narcolepsy
patients: a double blind study’, Sleep, 13, pp. 479–90.
Smith, K.M. (1999) ‘Drugs used in acquaintance rape’, Journal of the
American Pharmaceutical Association (Wash.), 39 (No 4), pp. 519–25.
Smythe, G. A., Brandstater, J. F. and Lazarus, L. (1975) ‘Serotonergic control
of rat growth hormone secretion’, Neuroendocrinology, 17, p. 245.
South, J., ‘Discover the regenerative effects of GHB’, International Antiaging
Systems. http://www.smart-drugs.com.
85
86
Spano, P. F., Tagliamonte, A., Tagliamonte, P. and Gessa, G. L. (1971)
‘Stimulation of brain dopamine synthesis by GHB’, Journal of
Neurochemistry, 18, pp. 1831–6.
Steel, G. C. (1968) ‘Clinical application of GHB as a sleep cover in lumbar
epidural block’, Proceedings of the Royal Society of Medicine, 61, p. 825.
Steele, M. T. and Watson, W. A. (1995) ‘Acute poisoning from GHB’,
Molecular Medicine, 92 (No 7), pp. 354–7.
Stephens, B. G. and Baselt, R. C. (1994) ‘Driving under the influence of
GHB?’, J. Anal. Toxicology, 18, pp. 357–358.
Stephens, R. G., Coleman, D. E. and Baselt, R. C. (1999) ‘In vivo stability of
endogenous GHB in post mortem blood’, Journal of Forensic Science, 44
(No 1), p. 231.
Stichting Adviesburo Drugs (1990) ‘Een Nieuwe Drugtrend: een beschrijving
over de opkomst en populariteit ven GHB en een analyse over het ontstaan
van de beeldvorming over rape drug’, Amsterdam, Netherlands.
Sturman, P., (2000) ‘Drug assisted sexual assault: a study for the Home Office
under the Police Research Award Scheme’, Home Office, London, United
Kingdom.
Takahara, J. et al. (1977) ‘Stimulatory effects of GHB on growth hormone and
prolactin release in humans’, Journal of Clinical Endocrinology &
Metabolism, 44, pp. 1014–7.
Vandevenne, L., Becker, J., Van de Velde, E. and Verstraete, A. (2000) ‘A case
of GBL overdose’, 20th International Congress of the European Association
of Poison Centres and Clinical Toxicologists (EAPCCT), Amsterdam,
Netherlands, 2000.
Vickers, M. D., (1968) ‘Gamma-hydroxybutyric acid’, Proceedings of the
Royal Society of Medicine, 61, pp. 821–4.
Vickers, M. (1969) ‘Gamma-hydroxybutyric acid’, International
Anesthesiology Clinics, 7, pp. 75–89.
Viera, A. J. and Yates, S. W. (1999) ‘Toxic ingestion of GHB’, Southern
Medical Journal, 92 (No 4), pp. 404–5.
Vree, T. B., Van der Kleijn, E. and Knop, H. J. (1976) ‘Rapid determination of
4-hydroxybutyric acid and 2-propylpentanoate in human plasma by means
of gas-liquid chromatography’, Journal of Chromatography, 121, pp. 150–2.
87
Walters, J. R., Roth, R. H. and Aghajanian, G. K. (1973) ‘Dopaminergic neu-
rons: similar biochemical and histochemical effects of GHB and acute
lesions of the nigro-neostriatal pathway’, Journal of Pharmacology and
Experimental Therapeutics, 186, pp. 630–9.
Ward, D., Morgenthaler, J. and Fowkes, S. (1998) GHB — the natural mood
enhancer, Smart Publications, California, United States.
Ward, D. (2000) GHB — the natural mood enhancer: the authoritative guide
to its responsible use, Smart Publications, California, United States.
Williams, H., Taylor, R. and Roberts, M. (1998) ‘Gamma-hydroxybutyrate
(GHB): a new drug of misuse’, Irish Medical Journal, 91 (No 2), pp. 56–7.
Williams, S. R., Turner, J. P. and Crunelli., V. (1995) ‘GHB promotes oscilla-
tory activity of rat and cat thalamocortical neurons by a tonic GABAB recep-
tor-mediated hyperpolarization’, Neuroscience, 66, pp. 133–41.
Williams, S. R. (1998) ‘Gamma-hydroxybutyric acid poisoning’, Western
Journal of Medicine, 168 (No 3), pp. 187–8.
Winter, J. C. (1981) ‘The stimulus properties of gamma-hydroxybutyrate’,
Psychopharmacology, 73 (No 4), pp. 372–5.
Winters, W. and Spooner, C. (1965) ‘A neurophysiological comparison of
GHB with pentobarbital in cats’, Clinical Neurophysiology, 18, pp. 287–96.
Woolverton, W. L. et al. (1999) ‘Evaluation of the reinforcing and discrimi-
native stimulus effects of GHB in rhesus monkeys’, Drug and Alcohol
Dependence, 54 (No 2), pp. 137–43.
Xie, X. and Smart, T. G. (1992) ‘GHB hyperpolarizes hippocampal neurones
by activating GABAB receptors’, European Journal of Pharmacology, 212,
pp. 291–4.
Yamada, Y. et al. (1967) ‘Effect of GBL and GHB on the EEG and sleep cycle
in man’, Electroencephalography and Clinical Neurophysiology, 22,
pp. 558–62.

Participants in the risk-assessment process
EMCDDA Scientific Committee
Members
Prof. Salme Ahlström, National Research and Development Centre for
Welfare and Health, Helsinki, Finland
Dr José Cabrera Forneiro, Anti-Drugs Agency, Madrid, Spain
Mr Pierre Campagna, Ministry of Health, Luxembourg
Dr Desmond Corrigan, School of Pharmacy, Trinity College, Dublin, Ireland
Dr Martin Frischer, Department of Medicines Management, Keele
University, Staffordshire, United Kingdom
Dr João Goulão, Drug Addiction Prevention and Treatment Service, Ministry
of Health, Lisbon, Portugal
Dr Katerina Matsa, Psychiatric Unit 18 ANO, Psychiatric Hospital of Athens,
Athens, Greece
Prof. Eckart Kühlhorn, Department of Sociology, University of Stockholm,
Stockholm, Sweden
Dr Ed Leuw, Research Documentation Centre, Ministry of Justice, The
Hague, Netherlands
Dr Aldo Perissino, Molière Hospital, Longchamps, Belgium
Dr Carlo Perucci, Agency for Public Health, Rome, Italy
Dr Anne-Marie Sindballe, National Board of Health, Copenhagen, Denmark
Dr Jean-Pol Tassin, Inserm U 114 Unit, Neuropharmacology, Paris, France
Prof. Dr Klaus Wanke, Department of Psychiatry, University of Saarlandes,
Homburg (Saar), Germany
Dr Wolfgang Werdenich, Special Detention Centre for the Treatment of
Addicted Offenders, Office of Justice, Vienna, Austria
Dr Astrid Skretting, National Institute for Alcohol and Drug Research, Oslo,
Norway
89
Representatives of the European Commission, Europol and
the European Agency for the Evaluation of Medicinal
Products (EMEA)
Mr Odd Hordvin, European Commission (DG SANCO), Luxembourg
Mr Carlos Oliveira Reis, European Commission (DG ENTR), Brussels,
Belgium
Prof. Spiros Vamvakas, Sector for New Chemical Entities, EMEA, London,
United Kingdom
Mr Richard Weijenburg, Europol, The Hague, Netherlands
Additional experts from the EU Member States
Dr Jocelyne Arditti, Centre Antipoison de Marseille, Salvator Hospital,
Marseille, France
Dr Robin Braithwaite, City Hospital NHS Trust, Birmingham, United
Kingdom
Dr Peter Ege, Municipality of Copenhagen, Administration for Family and
Labour Market Affairs, Copenhagen, Denmark
Dr Giorgio Forino, Division IV, Direzione Centrale per l’Analisi
Merceologica e Il Laboratori Chimico, Rome, Italy
Prof. Carmelo Furnari, University Tor Vergata, Forensic Toxicology
Laboratory, Rome, Italy
Ms Alice Guiton, Mission interministérielle de lutte contre la drogue et la
toxicomanie (MILDT), Paris, France
Dr Denis Hervé, Inserm U 114 Unit, Neuropharmacology, Paris, France
Dr Georgia Kostopanagiotou, Medical School, University of Athens, Athens,
Greece
Prof. Álvaro Lopes, Forensic Science Laboratory of the Criminal Police,
Lisbon, Portugal
Dr Robert Lousberg, Inspectorate of Health Care, Public Health Supervisory
Service of the Netherlands, The Hague, Netherlands
Dr Audrey O’Donnell, Forensic Science Laboratory, An Garda Síochana,
Dublin, Ireland
Mr Bertil Pettersson, National Institute of Public Health, Stockholm, Sweden
Dr Christina Poethko-Müller, Federal Institute for Drugs and Medical
Devices, Berlin, Germany
90
91
Dr Carla Rutgers, Ministry of Health, Welfare and Sport, Mental Health and
Addiction Policy Department, The Hague, Netherlands
Mr Bernard Vandenbosch, Department of Narcotic Drugs, Ministry of Public
Health and Environment, Brussels, Belgium
Dr Crista van Haeren, Institut National de Criminalistique, Brussels, Belgium
Other EMCDDA publications in the field of
new synthetic drugs and implementation of
the joint action
EMCDDA Insights series
New trends in synthetic drugs in the European Union: epidemiology and
demand-reduction responses
Insights series No 1
Published: 1997
ISBN: 92-9168-030-3
Price: EUR 20.50
Implementation of the joint action
Guidelines for the risk assessment of new synthetic drugs
Published: 1999
ISBN: 92-9168-061-3
Price: Free
Report on the risk assessment of ketamine in the framework of the joint
action on new synthetic drugs
Published: 2002
ISBN: 92-9168-123-7
Price: Free
Report on the risk assessment of 4-MTA in the framework of the joint
action on new synthetic drugs
Published: 1999
ISBN: 92-9168-087-7
Price: Free
Report on the risk assessment of MBDB in the framework of the joint
action on new synthetic drugs
Published: 1999
ISBN: 92-9168-063-X
Price: Free
92
European Monitoring Centre for Drugs and Drug Addiction
Report on the risk assessment of GHB in the framework of the joint action on
new synthetic drugs
Luxembourg: Office for Official Publications of the European Communities
2002 — 92 pp. —14.8 x 21 cm
ISBN 92-9168-122-9

15
 
 
 
 
 
 
 
 
 
 5
 
 
 
 
 
 
 
 
 
 6
TD
-39-01-045-EN-C
OFFICE FOR OFFICIAL PUBLICATIONS
OF THE EUROPEAN COMMUNITIES
L-2985 Luxembourg
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of
12 decentralised agencies set up by the European Union to carry out specialised tech-
nical or scientific work.
The Centre’s main goal is to provide ‘objective, reliable and comparable information at
European level concerning drugs and drug addiction and their consequences’.
Through the statistical, documentary and technical information it gathers, analyses
and disseminates, the Centre provides its audience — whether policy-makers, practi-
tioners in the drugs field or European citizens — with an overall picture of the drug
phenomenon in Europe.
The Centre’s main tasks are:
 collecting and analysing existing data;
 improving data-comparison methods;
 disseminating data; and
 cooperating with European and international bodies and organisations,
and with non-EU countries.
The EMCDDA works exclusively in the field of information.
Report on the 
risk assessment of GHB 
in the framework of the
joint action 
on new synthetic drugs
R
eport on the risk assessm
ent of G
H
B
 in the fram
ew
ork of the joint action on new
 synthetic drugs
ISBN 92-9168-122-9
,!7IJ2J1-gibcci!
›
 4
